Provisional Patents in Blood Anticlot Technology, Medications and
Medical Devices Published in 2010

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

US PATENT APPLICATIONS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED IN 2010



Application No.: US20100004196A1  Published: 07/Jan/2010

Title: HEPARAN SULFATE PROTEOGLYCAN COMPOSITION AND USE THEREOF

Applicant/Assignee: HOPITAUX UNIVERSITAIRES DE GENEVE RENSSELAER POLYTECHNIC INSTITUTE

Application No.: 12/486272   Filing Date: 17/Jun/2009

Abstract:The present invention relates to method for the preparation of glycosaminoglycan compositions, isolated glycosaminoglycan compositions obtainable therefrom, glycosaminoglycan compositions, kits and use thereof. More specifically, the present invention provides a method for isolating glycosaminoglycan compositions of the invention from human follicular fluid. The compositions, related methods and uses according to the present invention are useful in the treatment and/or prevention of thrombotic diseases, cell proliferation disorders, proteolysis and inflammation mediated cell invasion and infertility.

Priority: US20080132241P Applic. Date: 2008-06-17

Inventor: DE AGOSTINI ARIANE [CH]; LINHARDT ROBERT J [US]


Application No.: US20100004481A1  Published: 07/Jan/2010

Title: L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX

Applicant/Assignee: SIGNATURE R&D HOLDINGS

Application No.: 12/556968   Filing Date: 10/Sep/2009

Abstract:The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the derivatives of the present invention enhance at least one or more therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Priority: US2006-442027 Applic. Date: 2006-05-26; US2006-343557 Applic. Date: 2006-01-30; WO2004US24901 Applic. Date: 2004-07-29; US20030491331P Applic. Date: 2003-07-29

Inventor: CHANDRAN V RAVI [US]


Application No.: US20100004579A1  Published: 07/Jan/2010

Title: METHOD AND DEVICE FOR FILLING A SUPPLY DEVICE OF A THERAPY APPLIANCE

Applicant/Assignee:

Application No.: 12/310137   Filing Date: 23/Aug/2007

Abstract:The invention relates to a method for the filling of a metering apparatus of a therapy device having an extracorporeal circuit with which the metering apparatus is in communication such that an agent can be infused into the extracorporeal circuit during the operation of the therapy device by means of the metering device, with the method comprising the step of the dilution of a concentrate located in the metering apparatus, wherein the dilution of the concentrate located in the metering apparatus takes place in that the metering apparatus takes up the diluting agent from the extracorporeal circuit in the condition connected to the extracorporeal circuit.

Priority: DE200610039675 Applic. Date: 2006-08-24; WO2007EP07428 Applic. Date: 2007-08-23

Inventor: KOPPERSCHMIDT PASCAL [DE]


Application No.: US20100009007A1  Published: 14/Jan/2010

Title: Non-covalent modification of microparticles and process of preparing same

Applicant/Assignee: BAXTER INTERNATIONAL INC BAXTER HEALTHCARE S.A

Application No.: 12/170792   Filing Date: 10/Jul/2008

Abstract:The present disclosure is directed to surface-modified microparticles, pharmaceutical compositions thereof, and methods of making and using such particles. The surface-modified microparticles include a microparticle core, and at least one monolayer associated with the microparticle core. The monolayer comprises an amphiphilic polymer or non-ionic polymer grafted to an ionic polymer.

Priority:

Inventor: DARVARI RAMIN [US]; RASHBA-STEP JULIA E [US]; SCOTT TERRENCE L [US]


Application No.: US20100009913A1  Published: 14/Jan/2010

Title: Uses for Yerba Santa

Applicant/Assignee:

Application No.: 12/487942   Filing Date: 19/Jun/2009

Abstract:Methods of in vitro propagation of plants of the genus Eriodictyon are described, including, in particular embodiments, plants of the species E. californicum, E. trichocalyx and E. sessilifolium. Methods of producing transgenic plants of the genus Eriodictyon are also described, along with methods of producing recombinant proteins in such plants. Compositions and methods for administering recombinant proteins produced in these plants are also described.

Priority: US20080074376P Applic. Date: 2008-06-20

Inventor: KOPROWSKI HILARY [US]; POGREBNYAK NATALIA [US]; GOLOVKIN MAXIM [US]


Application No.: US20100009950A1  Published: 14/Jan/2010

Title: SUBSTITUTED ETHANOLAMINES

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/494002   Filing Date: 29/Jun/2009

Abstract:The present invention relates to new substituted ethanolamine adrenergic receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080076903P Applic. Date: 2008-06-30

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20100010357A1  Published: 14/Jan/2010

Title: Disposable air bag for a blood pressure measuring device and a method of making the same

Applicant/Assignee:

Application No.: 12/216661   Filing Date: 09/Jul/2008

Abstract:An disposable air bag for measuring blood pressure having a diaphragm and a nipple mounted therein, the diaphragm having a plurality of waves for allowing the diaphragm to expand easily out of the air bag and a clip for disconnecting and connecting the nipple to and from one end of an air hose the other end of which is connected to an electronic blood pressure measuring device. Also disclosed is a blood pressure measuring device having ABS storing means for storing the stretching characteristics of an air bag as a function of the air volume in the air bag, AABPOA calculating means for calculating the actual pressure on the artery, and systolic/diastolic algorithm calculating means for determining the systolic and diastolic blood pressures partially based on the AABPOA calculating means.

Priority:

Inventor: OSTROWIECKI MORRIS [JP]


Application No.: US20100015041A1  Published: 21/Jan/2010

Title: Class of Supramolecular Drug Molecules and Methods of Identification and Use Thereof

Applicant/Assignee:

Application No.: 11/813270   Filing Date: 17/Jan/2006

Abstract:This invention provides a class of supramolecular drugs and methods of identifying and using such drugs

Priority: US20050643998P Applic. Date: 2005-01-18; WO2006US01585 Applic. Date: 2006-01-17

Inventor: CALTAGIRONE GAETANO T [US]


Application No.: US20100016365A1  Published: 21/Jan/2010

Title: SUBSTITUTED 4-AMINO-PIPERIDINES

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/504792   Filing Date: 17/Jul/2009

Abstract:The present invention relates to new substituted 4-amino-piperidine opioid receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080081572P Applic. Date: 2008-07-17

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20100016778A1  Published: 21/Jan/2010

Title: APPARATUS FOR PURIFICATION OF BLOOD AND A PROCESS THEREOF

Applicant/Assignee:

Application No.: 12/310317   Filing Date: 16/Aug/2007

Abstract:The present invention is in relation to an apparatus for purification of blood and a method for assembling such apparatus. Also, the invention provides solution to the problem of kidney damage, wherein the damaged kidney can be replaced with the apparatus of instant invention to help in the purification of blood and thus helps the patients at large having kidney related disorders.

Priority: IN2006CH01502 Applic. Date: 2006-08-23; WO2007IN00347 Applic. Date: 2007-08-16

Inventor: CHATTOPADHYAY BUDHADITYA [IN]


Application No.: US20100018436A1  Published: 28/Jan/2010

Title: GLUE FROM SLAUGHTERHOUSE ANIMAL BLOOD

Applicant/Assignee:

Application No.: 12/358926   Filing Date: 23/Jan/2009

Abstract:Disclosed is a process for making an animal blood adhesive and the resulting adhesive composition. The adhesive is made by adding to fresh, whole animal blood, without dewatering the blood, an anticoagulant and a preservative. Lime is then added to the anticoagulated, preserved blood, and the pH is adjusted to between about 9 and about 11. A curing agent (such as potassium silicate, sodium silicate and aluminum dihydrogen phosphate) and ammonia are then added to the mixture to yield the animal blood adhesive. The adhesive can be made from any animal blood, such as bovine, porcine, or avian blood. The resulting adhesive is useful for adhering wood-based products, such as plywood and particle board.

Priority: US20080022948P Applic. Date: 2008-01-23

Inventor: GUNASEKARAN SUNDARAM [US]; LIN HAILIN [US]


Application No.: US20100021947A1  Published: 28/Jan/2010

Title: Detection meter and mode of operation

Applicant/Assignee: INTUITY MEDICAL, INC

Application No.: 12/457331   Filing Date: 08/Jun/2009

Abstract:A method for performing an assay to determine the presence or concentration of an analyte contained in a sample of body fluid by using a device comprising at least one analyte quantification member and a sensor associated therewith, the method includes: applying a first sample to the analyte quantification member

and detecting the presence or absence of an adequate sample volume

wherein upon detection of the absence of an adequate sample volume, initiating a finite timed period, and signaling the user to introduce a second sample of body fluid to the analyte quantification member. Associated arrangements and devices are also disclosed.

Priority: US20080129149P Applic. Date: 2008-06-06

Inventor: EMERY JEFFREY L [US]; TOMASCO MICHAEL F [US]; HU CHARLES [US]


Application No.: US20100022484A1  Published: 28/Jan/2010

Title: 4-Chromenonyl-1,4-dihydropyridines and their use

Applicant/Assignee:

Application No.: 11/989277   Filing Date: 12/Jul/2006

Abstract:The present application relates to novel 4-chromenonyl-1,4-dihydropyridines, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

Priority: DE200510034267 Applic. Date: 2005-07-22; WO2006EP06809 Applic. Date: 2006-07-12

Inventor: KUHL ALEXANDER [DE]; KOLKHOF PETER [DE]; HECKROTH HEIKE [DE]; SCHLEMMER KARL-HEINZ [DE]; FLAMME INGO [DE]; PEREZ SANTIAGO GIGUEROA [DE]; GIELEN-HAERTWIG HEIKE [DE]; GROSSER ROLF [DE]; ERGUEDEN JENS-KERIM [DE]; LANG DIETER [DE]


Application No.: US20100022936A1  Published: 28/Jan/2010

Title: WEARABLE ULTRAFILTRATION DEVICE

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 12/574128   Filing Date: 06/Oct/2009

Abstract:An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Priority: US2002-251937 Applic. Date: 2002-09-19; US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]


Application No.: US20100025274A1  Published: 04/Feb/2010

Title: MEDICAL DEVICE PACKAGE

Applicant/Assignee:

Application No.: 12/528561   Filing Date: 26/Feb/2008

Abstract:The present disclosure provides a package for a medical device containing a cavity for receiving the medical device, a first closure having a sealed portal therein and a second closure adjacent the first closure.

Priority: US20070904927P Applic. Date: 2007-03-05; WO2008US02458 Applic. Date: 2008-02-26

Inventor: STOPEK JOSHUA B [US]; KIRSCH DAVID [US]


Application No.: US20100028402A1  Published: 04/Feb/2010

Title: NANOPARTICLE-BASED ANTICOAGULANT

Applicant/Assignee:

Application No.: 12/446967   Filing Date: 23/Apr/2009

Abstract:A method for preventing or treating a blood clotting disorder is disclosed. The method includes administering a therapeutic effective amount of at least one nanoparticle-based anticoagulant to a subject afflicted with blood clotting disorder or potentially afflicted with a blood clotting disorder, wherein the at least one nanoparticle-based anticoagulant is a substituted fullerene, polyamidoamine (PAMAM) dendrimer or combination thereof.

Priority: WO2006US41838 Applic. Date: 2006-10-25

Inventor: DOBROVOLSKAIA MARINA [US]; MCNEIL SCOTT [US]; NEUN BARRY W [US]


Application No.: US20100028440A1  Published: 04/Feb/2010

Title: DRYING OF DRUG-CONTAINING PARTICLES

Applicant/Assignee:

Application No.: 12/309438   Filing Date: 09/Jul/2007

Abstract:A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes.

Priority: US20060807950P Applic. Date: 2006-07-21; WO2007IB01994 Applic. Date: 2007-07-09

Inventor: DOBRY DANIEL ELMONT [US]; KETNER RODNEY JAMES [US]; LYON DAVID KEITH [US]; MULLIN JAMES MATHEW [US]


Application No.: US20100030175A1  Published: 04/Feb/2010

Title: ABSORBENT ARTICLE

Applicant/Assignee:

Application No.: 12/448658   Filing Date: 27/Dec/2007

Abstract:An absorbent article comprises an absorbent interposed between a liquid-permeable surface sheet and a back sheet. The absorbent is constituted of a set of left and right absorbent elements arranged substantially along the longitudinal direction of the absorbent article. The absorbent element of one side is formed as a dogleg to the right in a top plan view whereas the absorbent element of the other side is formed as a dogleg to the left in a top plan view, so that the absorbent elements have an intersecting portion intersecting in at least the region containing the portion corresponding to the blood discharge opening of the wearer.

Priority: JP20060351165 Applic. Date: 2006-12-27; WO2007JP75109 Applic. Date: 2007-12-27

Inventor: KONAWA SATOKO [JP]


Application No.: US20100030325A1  Published: 04/Feb/2010

Title: BLOOD ANTICOAGULANT MATERIAL, COATING MATERIAL AND INDWELLING DEVICE COMPRISING THE SAME, AND TREATMENT USING BLOOD ANTICOAGULANT MATERIAL

Applicant/Assignee: JAPAN AS REP. BY PRES. OF NAT. CARDIOVASCULAR CTR MITSUBISHI CHEMICAL CORPORATION

Application No.: 12/515365   Filing Date: 16/Nov/2007

Abstract:A blood anticoagulant material is provided which has high expandability, reduced influence on living bodies, and can efficiently prevent blood coagulation. A multiblock copolymer having at least a structural unit represented by Formula (1), a structural unit represented by Formula (2), and a structural unit represented by Formula (3) is used: wherein, R1, R2, and R3 in Formulas (1) to (3) each independently represent a divalent organic group, and m and n each independently represent an integer of 2 to 5000.

Priority: JP20060312167 Applic. Date: 2006-11-17; WO2007JP72328 Applic. Date: 2007-11-16

Inventor: YAMAOKA TETSUJI [JP]; KATO SATOSHI [JP]; KASAI ATSUSHI [JP]; KAKINOKI SACHIRO [JP]


Application No.: US20100036359A1  Published: 11/Feb/2010

Title: Medical Device Package

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 12/544435   Filing Date: 20/Aug/2009

Abstract:The present disclosure provides a medical device package including a container for receiving a medical device having an area configured for storing at least one agent and a port for permitting the passage of a contact material between the outside the container and the area configured for storing the agent.

Priority: US2006-544503 Applic. Date: 2006-10-06

Inventor: STOPEK JOSHUA B [US]; COHEN MATTHEW D [US]; HOTTER JOSEPH [US]; DENMAN WILLIAM [US]


Application No.: US20100042137A1  Published: 18/Feb/2010

Title: ACUPUNCTURE AND ACUPRESSURE THERAPIES

Applicant/Assignee:

Application No.: 12/389248   Filing Date: 19/Feb/2009

Abstract:Described here are devices, methods, and kits for acupuncture or acupressure therapy. The devices may include a tissue-piercing member and a reservoir containing an agent. The devices and agents may be packaged as kits useful for relieving pain and/or treating various medical conditions. The devices, methods, and kits may enable less skilled practitioners to administer acupuncture or acupressure therapy, and may extend the duration of pain relief or other symptom relief.

Priority: US20080066327P Applic. Date: 2008-02-19; US20080061532P Applic. Date: 2008-06-13

Inventor: ORONSKY BRYAN T [US]; ORONSKY NEIL C [US]; ORONSKY ARNOLD L [US]


Application No.: US20100047162A1  Published: 25/Feb/2010

Title: METHODS OF PROCESSING MULTI-PHASIC DISPERSONS

Applicant/Assignee: BAXTER INTERNATIONAL INC BAXTER HEALTHCARE S.A

Application No.: 12/195149   Filing Date: 20/Aug/2008

Abstract:A method for processing multi-phasic dispersions is provided. The method comprises providing a multi-phasic dispersion including dispersed and continuous phases, providing a non-solvent, combining the multi-phasic dispersion and the non-solvent, and selectively effecting migration of the dispersed phase into or through the non-solvent such that the microparticles are separated from the dispersion.

Priority:

Inventor: PIRAN URI [US]


Application No.: US20100047292A1  Published: 25/Feb/2010

Title: METHODS OF PROCESSING MICROPARTICLES AND COMPOSITIONS PRODUCED THEREBY

Applicant/Assignee: BAXTER INTERNATIONAL INC BAXTER HEALTHCARE S.A

Application No.: 12/195182   Filing Date: 20/Aug/2008

Abstract:A method for processing multi-phasic dispersions is provided. The method comprises providing a multi-phasic dispersion including dispersed and continuous phases, positioning the multi-phasic dispersion within a chamber capable of being pressurized, pressurizing the chamber with a first gas to a pressure less than the supercritical pressure of the gas, and contacting the multi-phasic dispersion with the first gas.

Priority:

Inventor: TSUNG MEI [US]; EASSON JR D DAVIDSON [US]; MEHR EUGENE [US]; BOURHIS ALAIN L [US]


Application No.: US20100047315A1  Published: 25/Feb/2010

Title: Stent for Increasing Blood Flow to Ischemic Tissues and a Method of Using the Same

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 12/605251   Filing Date: 23/Oct/2009

Abstract:Stents and a method of using the stents to increase blood flow to ischemic tissues in a patient are disclosed.

Priority: US2003-678763 Applic. Date: 2003-10-02; US2001-846498 Applic. Date: 2001-04-30

Inventor: MANDRUSOV EVGENIA [US]; CONSIGNY PAUL [US]; HOSSAINY SYED FAIYAZ AHMED [US]; MIRZAEE DARY [US]


Application No.: US20100047832A1  Published: 25/Feb/2010

Title: Assessment of Patients with Sepsis to Determine a Requirement for Therapeutic Intervention with an Anti-Inflammatory and/or Anticoagulatory Agent

Applicant/Assignee:

Application No.: 12/517085   Filing Date: 19/Dec/2007

Abstract:Methods of selecting patients with sepsis for treatment with an anti-inflammatory and/or anticoagulatory agent are provided.

Priority: US20060876059P Applic. Date: 2006-12-20; WO2007DK50194 Applic. Date: 2007-12-19

Inventor: BANGERT KRISTIAN [DK]; UTTENTHAL LARS OTTO [ES]


Application No.: US20100048536A1  Published: 25/Feb/2010

Title: Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands

Applicant/Assignee:

Application No.: 12/396698   Filing Date: 03/Mar/2009

Abstract:The invention relates to novel compounds which bind to integrin receptors, their use as ligands of integrin receptors, in particular as ligands of the [alpha]v[beta]3 integrin receptor, and pharmaceutical preparations comprising these compounds.

Priority: DE20001028575 Applic. Date: 2000-06-14; US2003-344449 Applic. Date: 2003-09-08; WO2001EP09224 Applic. Date: 2001-08-09

Inventor: GENESTE HERVE [DE]; KLING ANDREAS [DE]; LAUTERBACH ARNULF [DE]; GRAEF CLAUDIA ISABELLA [DE]; SUBKOSKI THOMAS [DE]; HORNBERGER WILFRIED [DE]


Application No.: US20100056973A1  Published: 04/Mar/2010

Title: Therapeutic Compression Garments

Applicant/Assignee: FARROW MEDICAL INNOVATIONS, INC

Application No.: 12/391051   Filing Date: 23/Feb/2009

Abstract:A therapeutic compression apparatus includes a liner having a tubular body portion with a proximal opening for receiving a limb of a patient. The tubular body portion includes an inside region with an inside circumference that is sized to extend about and in contact with the limb. The inside circumference is substantially identical to a circumference of the limb at a respective area of contact. The tubular body portion includes an outside region having an outside circumference that varies from the inside circumference at respective cross-sections through the tubular body, such that a first function of a ratio of the difference between the inside circumference and the outside circumference at a respective cross-section through the tubular body, divided by the inside circumference at said respective cross-section, and a second function of the inside circumference at said respective cross-section determines, in part, a pressure exerted on the limb at said cross-section when compression is applied by said therapeutic compression apparatus.

Priority: US20080092459P Applic. Date: 2008-08-28

Inventor: FARROW WADE P [US]; CREIGHTON BARRY L [US]


Application No.: US20100062981A1  Published: 11/Mar/2010

Title: USE OF FIBRINOGEN AS A PROPHYLACTIC TREATMENT TO PREVENT BLEEDING DURING AND AFTER SURGERY AND AS A BIOMARKER TO IDENTIFY PATIENT WITH AN INCREASED RISK FOR EXCESSIVE BLEEDING AND BLOOD TRANSFUSION

Applicant/Assignee:

Application No.: 12/525516   Filing Date: 30/Jan/2008

Abstract:The present invention provides a method for preventing peri- and postoperative bleeding in subjects undergoing surgery, in particular subjects with a preoperative fibrinogen plasma level equal to or above the normal range. The method comprises administration of a substance with fibrinogen-like activity to the subject in an amount that result in a circulating fibrinogen plasma level of from about 1.0 g/L. The present invention also provides a method for determining the risk of subjects with a preoperative fibrinogen plasma level equal to or above the normal range to bleed postoperatively. Furthermore, the present invention provides means for predicting the necessity of blood or plasma transfusion after a subject with a preoperative fibrinogen plasma level equal to or above the normal range has been subject to a surgical procedure. The means involves measurement of the fibrinogen level of the subject before surgery and comparing the level with a risk curve.

Priority: DK20070001232 Applic. Date: 2007-08-29; US20070887441P Applic. Date: 2007-01-31; WO2008EP00710 Applic. Date: 2008-01-30

Inventor: JEPPSSON ANDERS [SE]; SKRTIC STANKO [SE]; BRUCE LENNART [SE]; JOHNSSON JOERGEN [SE]; HEDNER THOMAS [SE]


Application No.: US20100068242A1  Published: 18/Mar/2010

Title: Medical Devices for Localized Drug Delivery

Applicant/Assignee:

Application No.: 12/516236   Filing Date: 15/Nov/2007

Abstract:In certain embodiments, the invention relates to an implantable medical device that includes a body having an internal cavity. Receptor sites in the internal cavity may be adapted to repeatedly bind to, temporarily hold, and release an active agent. An opening may extend through the body and into the internal cavity to allow the active agent into and out of the internal cavity. This opening may be sized and shaped to prevent blood cells from entering the internal cavity through the opening while allowing the active agent to enter and/or exit the cavity via the opening. A polymeric structure may be located in the internal cavity. This polymeric structure may include artificial receptor site mimics for the active agent.

Priority: US20060873481P Applic. Date: 2006-12-07; WO2007US24069 Applic. Date: 2007-11-15

Inventor: CANTRELL GARY L [US]; BERBERICH DAVID W [US]


Application No.: US20100068725A1  Published: 18/Mar/2010

Title: DIRECT DETERMINATION OF VITAMIN D IN SERUM OR PLASMA

Applicant/Assignee:

Application No.: 12/517754   Filing Date: 30/Jan/2008

Abstract:A method for quantitating vitamin D metabolites directly in blood plasma or serum, without the need for prior purification of the vitamin D metabolites, comprising a digestion of the serum proteins with a serine protease such as proteinase K and sequence of steps for inhibiting the proteinase K activity in the competitive binding analysis. The advantages of this method are its high accuracy over the whole range of physiologically relevant values and that it can be easily adapted for a fully automated analysis of serum and plasma samples.

Priority: DE200710005099 Applic. Date: 2007-02-01; WO2008EP51162 Applic. Date: 2008-01-30

Inventor: ARMBRUSTER FRANZ PAUL [DE]; ROTH HEINZ-JUERGEN [DE]; FRIEDL SABINE [DE]; SCHUMANN CLAUDIA [DE]


Application No.: US20100069613A1  Published: 18/Mar/2010

Title: IMPLANTABLE MATERIALS AND COMPOSITIONS

Applicant/Assignee: INCEPT LLC

Application No.: 12/555970   Filing Date: 09/Sep/2009

Abstract:A method of concentrating proteins from whole blood comprising exposing whole blood to a covalently crosslinked hydrogel to remove water from the blood into the hydrogel to thereby concentrate the proteins in the whole blood. The hydrogel may absorb, for example, 50% or 90% of the water from the blood while excluding proteins with a weight of more than about 15,000 Daltons. In some embodiments, the hydrogels are dry, sterile, and spherical.

Priority: US2007-725751 Applic. Date: 2007-03-20; US2002-293453 Applic. Date: 2002-11-13; US2002-068807 Applic. Date: 2002-02-05; US1999-147897 Applic. Date: 1999-08-30; WO1997US16897 Applic. Date: 1997-09-22; US19960026526P Applic. Date: 1996-09-23; US19970039904P Applic. Date: 1997-03-04; US19970040417P Applic. Date: 1997-03-13

Inventor: PATHAK CHANDRASHEKHAR P [US]


Application No.: US20100076544A1  Published: 25/Mar/2010

Title: BIODEGRADABLE VASCULAR SUPPORT

Applicant/Assignee:

Application No.: 12/520976   Filing Date: 30/Jan/2008

Abstract:The embodiments described herein are directed to biodegradable stents comprising an inner biodegradable metal scaffold and an outer polymeric coating. The biodegradable coating consists preferentially of biodegradable polymers and may additionally include at least one pharmacologically active substance such as an anti-inflammatory, cytostatic, cytotoxic, antiproliferative, anti-microtubuli, antiangiogenic, antirestenotic (anti-restenosis), antifungicide, antineoplastic, antimigrative, athrombogenic and/or antithrombogenic agent.

Priority: DE200710005474 Applic. Date: 2007-01-30; DE200710034350 Applic. Date: 2007-07-24; WO2008DE00160 Applic. Date: 2008-01-30

Inventor: HOFFMANN ERIKA [DE]; HOFFMANN MICHAEL [DE]; HORRES ROLAND [DE]


Application No.: US20100078385A1  Published: 01/Apr/2010

Title: BLOOD CIRCUIT, BLOOD PURIFICATION CONTROL APPARATUS, AND PRIMING METHOD

Applicant/Assignee:

Application No.: 12/594081   Filing Date: 25/Mar/2008

Abstract:The present invention provides a blood circuit capable of automatically performing priming for safe treatments. The blood circuit includes: a hemofilter (56) purifying blood

a blood removal line that has an end connected to an inlet of the hemofilter (56) and that consists of a first blood removal line (84), a second blood removal line (88), and a third blood removal line (89)

a blood return line that has an end connected to an outlet of the hemofilter (56) and that consists of the first blood return line (92) and the second blood return line (94)

and an anticoagulant (bypass) line (90) reducing a difference between (a) a pressure of a priming fluid flowing in the blood removal line and (b) a pressure of the priming fluid flowing in the blood return line.

Priority: JP20070093625 Applic. Date: 2007-03-30; JP20070094381 Applic. Date: 2007-03-30; JP20070094382 Applic. Date: 2007-03-30; JP20070270706 Applic. Date: 2007-10-17; WO2008JP00718 Applic. Date: 2008-03-25

Inventor: KAWARABATA SHIGEKI [JP]; NAKAGAWA NORIAKI [JP]; FUJII JUNYA [JP]; KAMITO SHOGO [JP]


Application No.: US20100082012A1  Published: 01/Apr/2010

Title: DOUBLE BALLOON CATHETER AND METHODS FOR HOMOGENEOUS DRUG DELIVERY USING THE SAME

Applicant/Assignee: FOXHOLLOW TECHNOLOGIES, INC

Application No.: 12/564771   Filing Date: 22/Sep/2009

Abstract:The invention, in one embodiment, is directed to a catheter for site-specific delivery of a therapeutic agent to a blood vessel of a patient. The catheter further includes an elongated shaft having at least one inner lumen, a distal end and a proximal end and proximal and distal vessel-conforming balloons where each is separately positionable and inflatable, and when inflated, substantially restricts blood flow in the vessel and creates a treatment window of a defined but variable length for delivery of the therapeutic agent. The catheter optionally includes at least one marker band adjacent to the proximal balloon and at least one marker band adjacent to the distal balloon. At least one lateral aperture positioned in the window is in fluid communication with a drug delivery conduit located within either the inner shaft or the outer shaft to provide a homogeneous concentration of the therapeutic agent to the window.

Priority: US20080099127P Applic. Date: 2008-09-22

Inventor: HATTANGADI NEIL [US]; LERNER DANIEL [US]; OLIVERA RYAN [US]


Application No.: US20100086600A1  Published: 08/Apr/2010

Title: Flowable Carrier Matrix

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 12/635289   Filing Date: 10/Dec/2009

Abstract:A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority: US2006-504363 Applic. Date: 2006-08-14

Inventor: BEALS NEIL [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]


Application No.: US20100086953A1  Published: 08/Apr/2010

Title: Blood Coagulation Assays

Applicant/Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH

Application No.: 12/569714   Filing Date: 29/Sep/2009

Abstract:The invention relates to methods for determining the activity of a proteolytic coagulation factor of the blood coagulation cascade in a body fluid such as whole blood or plasma. A combination is provided in a reaction mixture. The combination comprises the sample and an activation agent for activating a proteolytic coagulation factor of the blood coagulation cascade or for activating the blood coagulation cascade. The effect of the activating on a reagent system comprising a cleavable moiety is evaluated. The cleavable moiety is or becomes bound to a chemiluminescent agent or a sensitizer agent or both. The chemiluminescent agent and the sensitizer agent are related in that, when in close proximity, energization of the sensitizer agent results in energization of the chemiluminescent agent. The effect of the activating is related to the activity of a proteolytic coagulation factor of the blood coagulation cascade wherein the effect is the extent of cleavage of the cleavable moiety.

Priority: EP20080017334 Applic. Date: 2008-10-02

Inventor: KAPPEL ANDREAS [DE]; LICHTE ANDREA [DE]; ZANDER NORBERT [DE]; TEIGELKAMP STEFAN [DE]; TEIGELKAMP SABINE [DE]


Application No.: US20100087455A1  Published: 08/Apr/2010

Title: SUBSTITUTED XANTHINE COMPOUNDS

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/574488   Filing Date: 06/Oct/2009

Abstract:The present invention relates to new substituted xanthine-based agents, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080102929P Applic. Date: 2008-10-06

Inventor: GANT THOMAS G [US]


Application No.: US20100087844A1  Published: 08/Apr/2010

Title: MECHANICAL THROMBECTOMY DEVICE

Applicant/Assignee: COOK INCORPORATED

Application No.: 12/245807   Filing Date: 06/Oct/2008

Abstract:A medical device for removing a thrombus from a blood vessel and a process thereof is presented. The device comprises an outer sheath with a plurality of lumens. A wire guide inserted through one of the lumens is used to place the device proximate to a thrombus. A chemical lysin agent is used to at least partially lyse the thrombus. A wire basket extended through the first lumen proximate to the thrombus is translated back and forth to generate a force that may be transmitted to the partially lysed thrombus assisting in the formation of smaller fragments. A vacuum coupled to the distal end of the second lumen is used to remove the lysed thrombus fragments.

Priority:

Inventor: FISCHER JR FRANK J [US]


Application No.: US20100092563A1  Published: 15/Apr/2010

Title: Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form

Applicant/Assignee: ICEUTICA PTY LTD

Application No.: 12/306948   Filing Date: 29/Jun/2007

Abstract:A method for producing a composition comprising nanoparticles of a biologically active compound.

Priority: AU20060903527 Applic. Date: 2006-06-30; WO2007AU00910 Applic. Date: 2007-06-29

Inventor: RAFFAELE CAMMARANO [AU]; FELIX MEISER [AU]; ALMAR POSTMA [AU]; FRANK CARUSO [AU]


Application No.: US20100092983A1  Published: 15/Apr/2010

Title: METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/573863   Filing Date: 05/Oct/2009

Abstract:The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20100092984A1  Published: 15/Apr/2010

Title: METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/573865   Filing Date: 05/Oct/2009

Abstract:The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20100094404A1  Published: 15/Apr/2010

Title: Methods of Making Biocomposite Medical Constructs and Related Constructs Including Artificial Tissues, Vessels and Patches

Applicant/Assignee:

Application No.: 12/576423   Filing Date: 09/Oct/2009

Abstract:The disclosure describes methods of making collagen based biocomposite constructs and related devices. The methods include: (a) winding at least one collagen fiber a number of revolutions about a length of a support member having a long axis, the winding having at least one defined pitch and/or fiber angle relative to the long axis of the support member to form an elongate construct

and (b) applying a fluid polymeric material, such as, for example, an acrylate emulsion and/or other thermoplastic material, onto the collagen fiber during the winding step. Optionally, the fluid polymeric material can include antibiotics and/or other therapeutic agents for additional function/utility.

Priority: US20080103995P Applic. Date: 2008-10-09; US20080138165P Applic. Date: 2008-12-17

Inventor: GREENHALGH KERRIANN [US]; LI MENGYAN [US]; KOOB THOMAS J [US]


Application No.: US20100100027A1  Published: 22/Apr/2010

Title: DEVICE FOR THE REMOVAL OF TOXIC SUBSTANCES FROM BLOOD

Applicant/Assignee: NEDERLANDSE ORGANISATIE VOOR TOEGEPASTNATUURWETEN- SCHAPPELIJK ONDERZOEK TNO

Application No.: 12/520005   Filing Date: 19/Dec/2007

Abstract:The present invention relates to a device for the removal of toxic substances from dialysate fluid, blood or blood plasma, said device comprising i) a sorption-filter (E) for removing toxins, toxic solutes, toxic small and middle-sized molecules and protein bound toxins from the dialysate fluid, blood or bloodplasma, said sorption filter comprising a nanostructured material, a porous polymer matrix or a combination of the two, ii) an inlet (4) for entry of dialysate fluid, blood or blood plasma into said device, iii) an outlet (5) for the removal of purified dialysate fluid, blood or blood plasma from said device, and iv) a conduit connecting said inlet with said outlet and holding said sorption filter such that said dialysate fluid, blood or blood plasma is forced through said sorption filter.

Priority: EP20060077295 Applic. Date: 2006-12-21; EP20070101127 Applic. Date: 2007-01-24; EP20070103515 Applic. Date: 2007-03-05; EP20070107504 Applic. Date: 2007-05-04; WO2007NL50669 Applic. Date: 2007-12-19

Inventor: SCHILTHUIZEN STEPHANUS FRANCISCUS [NL]; BATENBURG LAWRENCE FABIAN [NL]; SIMONIS FRANK [NL]; VERCAUTEREN FRANKY FLORY [NL]


Application No.: US20100105021A1  Published: 29/Apr/2010

Title: STABILISATION OF BIOLOGICAL CELL MARKERS

Applicant/Assignee: THE UNIVERSITY OF NOTTINGHAM

Application No.: 12/529997   Filing Date: 10/Mar/2008

Abstract:The invention provides compositions which stabilise the expression of cell surface markers. The invention further provides methods and kits comprising such compositions for use in stabilising the expression of cell surface markers. The invention is especially concerned with compositions for use in stabilising the expression of cell surface markers (such as cell activation markers) present on blood cells, such as platelets. The invention extends to methods, apparatus and kits for detecting platelet activation, and to kits for monitoring the efficacy of anti-thrombotic treatment regimes.

Priority: GB20070004488 Applic. Date: 2007-03-08; WO2008GB50169 Applic. Date: 2008-03-10

Inventor: MAY JANE ALISON [GB]; HEPTINSTALL STANLEY [GB]; FOX SUSNA CAROL [GB]


Application No.: US20100105091A1  Published: 29/Apr/2010

Title: Method for Measuring the Concentration of Transient Proteolytic Activity in Composite Biological Media Containing Cells

Applicant/Assignee: THROMBINOSCOPE B.V

Application No.: 12/513205   Filing Date: 02/Nov/2007

Abstract:A method is provided for determining in real time the course of thrombin activity in a sample of clotting blood or plasma as it appears in and disappears from the sample which comprises adding a signal substrate to said sample, said signal substrate causing a detectable signal related to the amount of conversion product formed upon reaction by the generated proteolytic activity, monitoring the signal development in time in said sample to provide a curve, and mixing said sample frequently so that clot formation occurs in a dense manner such that the majority of the sample remains fluid and that cell precipitation is inhibited, wherein said monitoring and mixing steps are repeated and performed in an alternate way.

Priority: EP20060022813 Applic. Date: 2006-11-02; WO2007EP09528 Applic. Date: 2007-11-02

Inventor: GIESEN PETER L A [NL]; TAPPENDEN KERRY [GB]; JONES WYNNE [GB]


Application No.: US20100105731A1  Published: 24/Jan/2008

Title: NOVEL BENZAMIDINE COMPOUND

Applicant/Assignee: AJINOMOTO CO. INC AJINOMOTO CO., INC

Application No.: 11/832895   Filing Date: 02/Aug/2007

Abstract:Compounds represented by formula (1) and pharmaceutically acceptable salt thereofs: wherein each symbol is as defined in the specification, are useful as inhibitors of an activated blood coagulation factor X. Compositions which contain, as an active ingredient, an FXa selective low-molecular weight FXa inhibitor having a short serum half-life are particularly useful as anticoagulants for an extracorporeal blood circuit.

Priority: JP20050026949 Applic. Date: 2005-02-02; WO2006JP302202 Applic. Date: 2006-02-02

Inventor: TAKAYANAGI MASARU [JP]; TAKEHANA SHUNJI [JP]; OTANI KAYO [JP]; SAITOU YUKI [JP]


Application No.: US20100110416A1  Published: 06/May/2010

Title: MEASURING HEMATOCRIT AND ESTIMATING HEMOGLOBIN VALUES WITH A NON-INVASIVE, OPTICAL BLOOD MONITORING SYSTEM

Applicant/Assignee: HEMA METRICS, LLC

Application No.: 12/265392   Filing Date: 05/Nov/2008

Abstract:An optical blood monitoring system with a ratiometric model determines hematocrit values for a hemodialysis patient, from which hemoglobin values for the patient are estimated. The ratiometric model is calibrated, normally against a cell counter, using blood from a blood bank. The blood from a blood bank is preserved in a long term preservative which is typically different than that found in clinical settings. The hematocrit value determined by the ratiometric model is scaled by scaling factor so that the estimated hemoglobin level output from the monitor consistently matches that measured in a clinical setting. The hematocrit scaling factor is substantially about 1.033 when the patient's blood sample is stored in a short term preservative ethylene diamine tetra acetic, and is substantially about 1.06 when the hematocrit is measured in the blood sample without preservative being added to the blood sample. The hemoglobin value can also be adjusted for altitude.

Priority:

Inventor: BARRETT LOUIS LEEGRANDE [US]; PETERSON DAVID WAYNE [US]; SAMMANN KRISTIAN ALLEN [US]


Application No.: US20100112069A1  Published: 06/May/2010

Title: Flowable Carrier Matrix

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 12/634323   Filing Date: 09/Dec/2009

Abstract:A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority: US2006-504363 Applic. Date: 2006-08-14

Inventor: BEALS NEIL [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]


Application No.: US20100112079A1  Published: 06/May/2010

Title: Thyroid Hormone Analogs and Methods of Use

Applicant/Assignee: ORDWAY RESEARCH INSTITUTE, INC

Application No.: 12/626068   Filing Date: 25/Nov/2009

Abstract:Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Priority: US2004-943072 Applic. Date: 2004-09-15; US20030502721P Applic. Date: 2003-09-15

Inventor: MOUSA SHAKER A [US]; DAVIS FAITH B [US]; DAVIS PAUL J [US]


Application No.: US20100113345A1  Published: 06/May/2010

Title: PREPARATION OF LOW BLEEDING ANTICOAGULANT FUSION PROTEIN AND ITS USE

Applicant/Assignee: BEIJING SANLY SCI-TECH DEVELOP INC. LTD INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA

Application No.: 12/519309   Filing Date: 11/Dec/2007

Abstract:Provided is an anticoagulant fusion protein comprising oligopeptide recognizable and cleavable by either factor XIa and factor Xa or thrombin and factor Xa. Also provided are the preparation method of the anticoagulant fusion protein and medicinal use thereof.

Priority: CN20061165756 Applic. Date: 2006-12-15; WO2007CN03526 Applic. Date: 2007-12-11

Inventor: WU ZUZE [CN]; YU AIPING [CN]; ZHANG CHUANLING [CN]; TANG ZHONGXIONG [CN]


Application No.: US20100113606A1  Published: 06/May/2010

Title: AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/611596   Filing Date: 03/Nov/2009

Abstract:The present invention relates to new aminopropanol modulators of beta-1 adrenergic receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080111592P Applic. Date: 2008-11-05

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20100114001A1  Published: 06/May/2010

Title: EXTRACORPOREAL BLOOD TREATMENT AND SYSTEM HAVING REVERSIBLE BLOOD PUMPS

Applicant/Assignee: CHF SOLUTIONS, INC

Application No.: 12/613588   Filing Date: 06/Nov/2009

Abstract:An extracorporeal blood processing method using a blood circuit comprising a pair of blood passages attached to opposite flow ends of a blood treatment device and said blood circuit is mounted on a blood pump console, the method includes: withdrawing blood from a vascular system of a human patient and drawing the blood into the blood circuit

pumping the withdrawn blood through one of the pair of blood passages using a first blood pump of the console and into the blood treatment device

pumping the treated blood from the treatment device through the other of the pair of blood passages using a second blood pump of the console

infusing the treated blood from the other blood passage and into the vascular system of the patient, and periodically reversing a flow direction of blood through the pair of blood passages and blood treatment device.

Priority: US2004-002442 Applic. Date: 2004-12-03

Inventor: O'MAHONY JOHN J [US]


Application No.: US20100114254A1  Published: 06/May/2010

Title: SUBCLAVIAN ANSAE STIMULATION

Applicant/Assignee: MEDTRONIC, INC

Application No.: 12/262867   Filing Date: 31/Oct/2008

Abstract:Techniques for improving cardiac performance by applying stimulation to the subclavian ansae nerve of a patient are disclosed. In one example, a method comprises identifying a human patient as having a cardiac condition, and delivering stimulation therapy to a subclavian ansae nerve of a human patient with a stimulation electrode.

Priority:

Inventor: KORNET LILIAN [NL]


Application No.: US20100116279A1  Published: 17/Mar/2005

Title: Devices for maintaining patency of surgically created channels in tissue

Applicant/Assignee: BRONCUS TECHNOLOGIES, INC

Application No.: 10/894876   Filing Date: 19/Jul/2004

Abstract:Devices and methods for altering gaseous flow within a lung to improve the expiration cycle of an individual, particularly individuals having chronic obstructive pulmonary disease. The methods and devices create channels in lung tissue and maintain the patency of these surgically created channels in tissue. Maintaining the patency of the channels allows air to pass directly out of the lung tissue which facilitates the exchange of oxygen ultimately into the blood and/or decompresses hyper-inflated lungs.

Priority: US2001-908177 Applic. Date: 2001-07-18; US2000-633651 Applic. Date: 2000-08-07; US20030488332P Applic. Date: 2003-07-18; US19990147528P Applic. Date: 1999-08-05; US20000176141P Applic. Date: 2000-01-14

Inventor: COOPER JOEL D [US]


Application No.: US20100116694A1  Published: 13/May/2010

Title: Medical Device Package

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 12/544444   Filing Date: 20/Aug/2009

Abstract:The present disclosure provides a medical device package including a container for receiving a medical device having an area configured for storing at least one agent and a port for permitting the passage of a contact material between the outside the container and the area configured for storing the agent.

Priority: US2006-544503 Applic. Date: 2006-10-06

Inventor: STOPEK JOSHUA B [US]; COHEN MATTHEW D [US]; HOTTER JOSEPH [US]; DENMAN WILLIAM [US]


Application No.: US20100119510A1  Published: 13/May/2010

Title: LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 12/691895   Filing Date: 22/Jan/2010

Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4 I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Priority: US2009-401401 Applic. Date: 2009-03-10; US2007-955678 Applic. Date: 2007-12-13; US2005-198801 Applic. Date: 2005-08-05; US2004-850587 Applic. Date: 2004-05-20; US2002-245122 Applic. Date: 2002-09-17; US20010324165P Applic. Date: 2001-09-21; US20020402317P Applic. Date: 2002-08-09

Inventor: PINTO DONALD J P [US]; QUAN MIMI L [US]; ORWAT MICHAEL J [US]; LI YUN-LONG [US]; HAN WEI [US]; QIAO JENNIFER X [US]; LAM PATRICK Y S [US]; KOCH STEPHANIE L [US]


Application No.: US20100119568A1  Published: 13/May/2010

Title: Apparatus and method for transdermal delivery of parathyroid hormone agents

Applicant/Assignee: ALZA CORPORATION

Application No.: 12/455830   Filing Date: 08/Jun/2009

Abstract:An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.

Priority: US2005-084634 Applic. Date: 2005-03-18; US20040571304P Applic. Date: 2004-05-13; US20040585276P Applic. Date: 2004-07-01; US20050643660P Applic. Date: 2005-01-12

Inventor: AMERI MAHMOUD [US]; CORMIER MICHEL J N [US]; MAA YUH-FUN [US]; DADDONA PETER E [US]; KAMBERI MARIKA [US]


Application No.: US20100119582A1  Published: 13/May/2010

Title: Device for the Treatment and Prevention of Disease, and Methods Related Thereto

Applicant/Assignee:

Application No.: 12/625582   Filing Date: 25/Nov/2009

Abstract:Disclosed are implantable devices for delivering a drug into the blood stream of a vessel or into the vessel wall of a subject's body to treat or prevent vascular or cardiovascular disease, such as vascular plaque, cardiovascular plaque, and diseases attributable to inflammation, such as arteriosclerosis, diabetes, rheumatoid arthritis, and Alzheimer's disease. The devices of the present invention comprise a biodegradable matrix that degrades gradually and vanishes over a period of time, and have a ring-like, flag-like, or plaster-like configuration. The flag-like configuration comprises a holding structure and at least one flag. These flags are preferably elastic, and may be constructed from fibers, woven tissue, strings, sheets, or any combination thereof. Disclosed devices may comprise more than one drug, or varying concentrations of the same drug. Also disclosed are methods related thereto.

Priority: US2004-784331 Applic. Date: 2004-02-23; US20030448930P Applic. Date: 2003-02-22

Inventor: BOERGER LARS [DE]; DAUM WOLFGANG [US]


Application No.: US20100120015A1  Published: 13/May/2010

Title: METHOD OF COLLECTING PLACENTAL STEM CELLS

Applicant/Assignee:

Application No.: 12/618664   Filing Date: 13/Nov/2009

Abstract:A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.

Priority: US2005-187400 Applic. Date: 2005-07-21; US2001-004942 Applic. Date: 2001-12-05; US20000251900P Applic. Date: 2000-12-06

Inventor: HARIRI ROBERT J [US]


Application No.: US20100120917A1  Published: 13/May/2010

Title: BUTYLAMMONIUM MODULATORS OF FATTY ACID TRANSPORT

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/615320   Filing Date: 10/Nov/2009

Abstract:The present invention relates to new butylammonium modulators of fatty acid transport, and/or removal of toxic acyl-CoA compounds, pharmaceutical compositions thereof, and methods of use thereof

Priority: US20080113239P Applic. Date: 2008-11-11

Inventor: GANT THOMAS G [US]; SHAHBAZ MANOUCHEHR [US]; HODULIK CRAIG [US]


Application No.: US20100124550A1  Published: 20/May/2010

Title: AMIDE INHIBITORS OF RENIN

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/622933   Filing Date: 20/Nov/2009

Abstract:The present invention relates to new amide inhibitors of renin, pharmaceutical compositions thereof, and methods of use thereof

Priority: US20080116348P Applic. Date: 2008-11-20

Inventor: GANT THOMAS G [US]; SHAHBAZ MANOUCHEHR M [US]


Application No.: US20100124745A1  Published: 20/May/2010

Title: Methods ofr the detection of gene trannscripts in blood and uses thereof

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/573856   Filing Date: 05/Oct/2009

Abstract:The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20100124746A1  Published: 20/May/2010

Title: Method for the detection of gene transcripts in blood and uses thereof

Applicant/Assignee: GENENEWS, INC,

Application No.: 12/587382   Filing Date: 05/Oct/2009

Abstract:The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20100125052A1  Published: 20/May/2010

Title: ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 12/616735   Filing Date: 11/Nov/2009

Abstract:The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor.

Priority: US20080114948P Applic. Date: 2008-11-14

Inventor: LU GENMIN [US]; SINHA UMA [US]


Application No.: US20100125094A1  Published: 20/May/2010

Title: PYRROLIDINYL MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/618934   Filing Date: 16/Nov/2009

Abstract:The present invention relates to new pyrrolidinyl modulating nicotinic acetylcholine receptor compounds, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080115377P Applic. Date: 2008-11-17

Inventor: GANT THOMAS G [US]; SHAHBAZ MANOUCHEHR M [US]; HODULIK CRAIG [US]


Application No.: US20100125240A1  Published: 20/May/2010

Title: THERAPEUTIC MATERIAL DELIVERY SYSTEM FOR TISSUE VOIDS AND CANNULATED IMPLANTS

Applicant/Assignee:

Application No.: 12/414194   Filing Date: 30/Mar/2009

Abstract:Described herein is a novel drug delivery assembly having particular applicability to the field of orthopedic and surgical medicine. The devices and assemblies described herein enable the efficient application and retention of potentially expensive therapeutic materials to very specific locations, particularly those associated with voids in bone and tissue. One particularly unique aspect of the present invention involves the introduction of constructs which promote the retention of therapeutic material in the target area of application for beneficial use, for example by forming a proximal barrier that prevents leakage of the therapeutic material out of the target area. Additionally, the present invention provides unique devices and methods for surgical introduction of such constructs. The present invention finds particular application in connection with introduction of stem and progenitor cells, bioactive molecules and bone scaffold materials in conjunction with bone voids and with the use of cannulated implants, such as bone screws (also surgical screws) and pins. The present invention also has beneficial use in the delivery of cancer drugs, antimicrobials, bone cements and other therapeutic materials.

Priority: US20080116465P Applic. Date: 2008-11-20; US20090154718P Applic. Date: 2009-02-23

Inventor: SPEDDEN RICHARD H [US]; SCHON LEW C [US]; PINGEL LAURA J [US]


Application No.: US20100130543A1  Published: 27/May/2010

Title: PYRAZOLE CARBOXAMIDE INHIBITORS OF FACTOR XA

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/558906   Filing Date: 14/Sep/2009

Abstract:The present invention relates to new pyrazole carboxamide inhibitors of factor Xa, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080096869P Applic. Date: 2008-09-15

Inventor: GANT THOMAS G [US]; SHAHBAZ MANOUCHERHR M [US]


Application No.: US20100130905A1  Published: 27/May/2010

Title: METHOD AND DEVICE FOR CHECKING THE CORRECT COUPLING OF A SUPPLY DEVICE TO A THERAPY DEVICE

Applicant/Assignee:

Application No.: 12/451565   Filing Date: 13/May/2008

Abstract:This invention relates to a method for checking the correct coupling of an adding device to a therapeutic appliance, which includes an extracorporeal circuit with which the adding device is connected such that a drug can be introduced into the extracorporeal circuit by means of the adding device during operation of the therapeutic appliance, wherein the adding device is coupled to the extracorporeal circuit on the suction side of a pump disposed in the extracorporeal circuit, wherein a portion in the region of negative pressure of the extracorporeal circuit in connection with a portion of the adding device is closed with respect to the other parts of the extracorporeal circuit, and wherein the pressure in this closed portion is varied and measured.

Priority: DE200710024463 Applic. Date: 2007-05-25; WO2008EP03835 Applic. Date: 2008-05-13

Inventor: NUERNBERGER THOMAS [DE]; BLASEK MARCO [DE]; KLOEFFEL PETER [DE]


Application No.: US20100135986A1  Published: 03/Jun/2010

Title: COMPOSITIONS FOR ANTI-FIBRINOLYTIC TREATMENT

Applicant/Assignee:

Application No.: 12/452280   Filing Date: 26/Jun/2008

Abstract:The present invention concerns the use of a neutralising antibody for matrix metalloproteinase-10 (MMP-10) in the preparation of a medicine useful for anti-fibrinolytic treatment, and for haemorrhages and haemorrhagic complications of various etiologies.

Priority: ES20070001786 Applic. Date: 2007-06-26; WO2008ES00453 Applic. Date: 2008-06-26

Inventor: ORBE LOPATEGUI JOSUNE [ES]; RODRIGUEZ GARCIA JOSE ANTONIO [ES]; PARAMO FERNANDEZ JOSE ANTONIO [ES]; SERRANO VARGAS ROSARIO [ES]


Application No.: US20100137744A1  Published: 03/Jun/2010

Title: INTRAVENOUS INDWELLING CATHETER

Applicant/Assignee:

Application No.: 11/719720   Filing Date: 26/Oct/2005

Abstract:The invention relates to an indwelling catheter, in particular an intravenous indwelling catheter for emergency treatment. Said catheter comprises a housing (1) and a puncturing cannula (2), which can be introduced into and removed from the housing interior in the longitudinal direction of the housing (1) and which extends through a front housing opening, in such a way that when said cannula (2) is fully introduced, an entry opening is located outside the housing (1). A collection component (5) stores a blood sample, said component being held in a displaceable manner on the housing (1) with the aid of a fixing element (9) and being displaced between a coupled position, in which a self-replenishing reservoir (7), which is configured in the collection component (5), is in contact with an exit opening of the cannula (2) in order to receive a sample of blood that traverses the cannula (2) and an uncoupled position, in which the reservoir (7) is separated from the exit opening of the cannula (2) and the collection component (5) is held on the housing (1) by means of the fixing element (9).

Priority: DE200410055989 Applic. Date: 2004-11-19; WO2005DE01945 Applic. Date: 2005-10-26

Inventor: NOTTER MICHAEL [DE]


Application No.: US20100137778A1  Published: 03/Jun/2010

Title: Automated Blood Sampler and Analyzer

Applicant/Assignee:

Application No.: 12/326857   Filing Date: 02/Dec/2008

Abstract:An automated blood sampler integratable with a glucose monitor comprises a catheter connected to a tube-set forming a single blood passageway

a clamp-on air-bubble sensor and a occlusion sensor externally attached to the tube set

a single peristaltic pump and two 3-way pinch valves attached to the tube set and control fluid flow. The sampler draws blood from a stationary patient, samples the blood for analytical measurement of blood parameters

after which the passageway is rinsed, the blood re-infused, and slow saline infusion prevents vein collapse. The cycle repeats at user or predefined intervals. In another preferred embodiment, blood is not re-infused, and only one 3-way pinch valve is used.

Priority:

Inventor: KUNJAN KISLAYA [US]; LLOYD JR FRANK P [US]


Application No.: US20100143317A1  Published: 10/Jun/2010

Title: INFARCT AREA PERFUSION-IMPROVING COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR

Applicant/Assignee:

Application No.: 12/629361   Filing Date: 02/Dec/2009

Abstract:The described invention provides pharmaceutical compositions for treating an infarct area injury and methods of treating or repairing the infarct area injury in a revascularized subject in the aftermath of an acute myocardial infarction resulting from a natural disease process by administering to the subject parenterally through a catheter a sterile pharmaceutical composition containing a therapeutically effective amount of a nonexpanded sterile isolated chemotactic hematopoietic stem cell product as a first therapeutic agent and optionally a therapeutically effective amount of at least one compatible second therapeutic agent. The infarct area-improving amount of the sterile isolated chemotactic hematopoietic stem cell product comprises an enriched population of isolated autologous CD34+ cells containing a subpopulation of potent cells expressing CXCR-4 and having CXCR-4-mediated chemotactic activity such that the enriched population of isolated autologous CD34+ hematopoietic stem cells provides at least 0.5106 potent CD34+ cells expressing CXCR-4 and having CXCR-4 mediated chemotactic activity.

Priority: US20080119552P Applic. Date: 2008-12-03; US20090169850P Applic. Date: 2009-04-16

Inventor: PECORA ANDREW [US]; PRETI ROBERT [US]


Application No.: US20100143420A1  Published: 10/Jun/2010

Title: MULTI-PHASIC PHARMACEUTICAL FORMULATIONS OF POORLY WATER-SOLUBLE DRUGS FOR REDUCED FED/FASTED VARIABILITY AND IMPROVED ORAL BIOAVAILABILITY

Applicant/Assignee:

Application No.: 12/523445   Filing Date: 22/Jan/2008

Abstract:Pharmaceutical formulations are disclosed comprising a multi-phasic pharmaceutical composition comprising an active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is in a particulate state, a solubilized state, or in both a particulate state and in a solubilized state

a solvent

a non-miscible liquid

a stabilizer, and water

wherein the pharmaceutical formulation is an oral dosage form. Such pharmaceutical formulations are capable of reducing the fed/fast variability and improving oral bioavailability to which a number of active pharmaceutical ingredients are susceptible. The pharmaceutical formulations of the invention, therefore are bioequivalent in fed and fasted states and improved oral bioavailability.

Priority: US20070881470P Applic. Date: 2007-01-22; WO2008US51639 Applic. Date: 2008-01-22

Inventor: SHENOY DINESH [IN]; LEE ROBERT [US]


Application No.: US20100143481A1  Published: 10/Jun/2010

Title: METHOD OF PREPARING SOLID DOSAGE FORMS OF MULTI-PHASIC PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee:

Application No.: 12/513203   Filing Date: 08/Nov/2007

Abstract:Pharmaceutical formulations comprising a multi-phasic pharmaceutical composition, and an adsorbent carrier, where the pharmaceutical formulation is a solid dosage form. Methods for preparing such pharmaceutical compositions are described.

Priority: US20060857511P Applic. Date: 2006-11-08; WO2007US84141 Applic. Date: 2007-11-08

Inventor: SHENOY DINESH [IN]; LEE ROBERT [US]; SOPPIMATH KUMARESH [US]; BETAGERI GURU [US]


Application No.: US20100144616A1  Published: 10/Jun/2010

Title: Neuroprotective methods and reagents

Applicant/Assignee: CURIS, INC

Application No.: 12/220865   Filing Date: 28/Jul/2008

Abstract:One aspect of the present application relates to a method for limiting damage to neuronal cells by ischemic or epoxic conditions, e.g., such as may be manifest by a reduction in brain infarct volume, by administering to an individual a hedgehog therapeutic or ptc therapeutic in an amount effective for reducing cerebral infarct volume.

Priority: US2004-849704 Applic. Date: 2004-05-19; US1999-418221 Applic. Date: 1999-10-14; US1997-883656 Applic. Date: 1997-06-27

Inventor: MAHANTHAPPA NAGESH K [US]


Application No.: US20100144667A1  Published: 10/Jun/2010

Title: METHODS FOR FUCOIDAN PURIFICATION FROM SEA WEED EXTRACTS

Applicant/Assignee:

Application No.: 12/449712   Filing Date: 01/Feb/2008

Abstract:Methods for purifying fucoidan in extracts from brown seaweed are disclosed. In particular, methods of purifying fucoidan in the extract to remove heavy metal ions, bacterial and endotoxin contaminants, and other impurities are disclosed. The methods include the use of a chelating agent, selective precipitation, and filtration.

Priority: US20070891287P Applic. Date: 2007-02-23; WO2008US01425 Applic. Date: 2008-02-01

Inventor: SHAKLEE PATRICK N [US]; BAHR-DAVIDSON JENNIFER [US]; PRASAD SRINIVASA [US]; JOHNSON KIRK [US]


Application No.: US20100152189A1  Published: 17/Jun/2010

Title: NOVEL POLYMORPHOUS FORM AND THE AMORPHOUS FORM OF 5-CHLORO-N-({ (5S)-2-OXO-3[4-(3-OXO-4-MORPHOLINYL(-PHENYL]-1,3-OXAZOLIDINE-5-YL}-METHYL)-2-THIOPHENE CARBOXAMIDE

Applicant/Assignee: BAYER HEALTHCARE AG

Application No.: 12/089095   Filing Date: 22/Sep/2006

Abstract:The present invention relates to a novel polymorphic form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene-carboxamide, processes for their preparation, medicaments comprising these forms, and their use in the control of diseases.

Priority: DE200510047563 Applic. Date: 2005-10-04; DE200510047564 Applic. Date: 2005-10-04; WO2006EP09202 Applic. Date: 2006-09-22

Inventor: GRUNENBERG ALFONS [DE]; LENZ JANA [DE]; BRAUN GERHARD ARNOLD [DE]; KEIL BIRGIT [DE]; THOMAS CHRISTIAN R [DE]


Application No.: US20100152649A1  Published: 17/Jun/2010

Title: Apparatus and method for transdermal delivery of parathyroid hormone agents

Applicant/Assignee: ALZA CORPORATION

Application No.: 12/459499   Filing Date: 01/Jul/2009

Abstract:An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.

Priority: US2005-084634 Applic. Date: 2005-03-18; US20040571304P Applic. Date: 2004-05-13; US20040585276P Applic. Date: 2004-07-01; US20050643660P Applic. Date: 2005-01-12

Inventor: AMERI MAHMOUD [US]; CORMIER MICHEL J N [US]; MAA YUH-FUN [US]; DADDONA PETER E [US]; KAMBERL MARIKA [US]


Application No.: US20100158796A1  Published: 24/Jun/2010

Title: AMIDES OF HYALURONIC ACID AND THE DERIVATIVES THEREOF AND A PROCESS FOR THEIR PREPARATION

Applicant/Assignee:

Application No.: 12/623253   Filing Date: 20/Nov/2009

Abstract:An amide of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of general formula (1).: wherein R-NR6R7, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid

R1, R2, R3, R4-H, SO3-, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH2)2-COOY

Y=negative charge, or H

R5--CO-CH3, H, SO3-, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acylic group of hyaluronic acid

R6=is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted

R7=is H or an aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted

wherein at least one of R or R5 forms an amide group.

Priority: IT1998PD00169 Applic. Date: 1998-07-06; US2002-220853 Applic. Date: 2002-09-06; WO1999IB01254 Applic. Date: 1999-07-06

Inventor: BELLINI DAVIDE [IT]; TOPAI ALESSANDRA [IT]


Application No.: US20100160446A1  Published: 24/Jun/2010

Title: 3,4-DIMETHOXYPHENETHYLAMINE MODULATORS OF L-TYPE CALCIUM CHANNEL

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/641454   Filing Date: 18/Dec/2009

Abstract:The present invention relates to new 3,4-dimethoxyphenethylamine modulators of L-type calcium channel activity, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080139343P Applic. Date: 2008-12-19

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20100160629A1  Published: 24/Jun/2010

Title: CYCLIC AMIDE DERIVATIVE, AND ITS PRODUCTION AND USE

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 12/715930   Filing Date: 02/Mar/2010

Abstract:The present invention provides a cyclic amide derivative useful as a drug for treating thrombosis, which is represented by the formula (I): wherein R1 represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent chain hydrocarbon group, a represents 0, 1, or 2, X1 represents an optionally substituted lower alkylene or an optionally substituted lower alkenylene, Y1 represents -C(O)-, -S(O)- or -S(O)2-, A represents a piperazine ring which may be further substituted or a piperidine ring which may be further substituted, X2 represents a bond or an optionally substituted lower alkylene, Y2 represents -C(O)-, -S(O)-, -S(O)2- or -C(-NR7)-, X3 represents an optionally substituted C1-4 alkylene or an optionally substituted C2-4 alkenylene, Z3 represents -N(R4)-, -O- or a bond, Z1 represents -C(R2)(R2')-, -N(R2)-, etc., and Z2 represents -C(R3)(R3')-, -N(R3)-, etc., or a salt thereof.

Priority: JP20040152000 Applic. Date: 2004-05-21; US2006-596089 Applic. Date: 2006-11-09; WO2005JP09711 Applic. Date: 2005-05-20

Inventor: KUBO KEIJI [JP]; IMAEDA YASUHIRO [JP]


Application No.: US20100160898A1  Published: 24/Jun/2010

Title: METHOD AND APPARATUS FOR STORAGE AND/OR INTRODUCTION OF IMPLANT FOR HOLLOW ANATOMICAL STRUCTURE

Applicant/Assignee: TYCO HEALTHCARE GROUP, LP

Application No.: 12/642699   Filing Date: 18/Dec/2009

Abstract:Apparatus for advancing a vascular implant into a blood vessel. The apparatus comprises a first elongate member, the first elongate member having sufficient column strength to function as a pusher member

and a second elongate member, the second elongate member being thinner than the first elongate member and extending to a distal end located at a first point which is at or near a distal end of the first elongate member. The elongate members form an implant retaining portion while the distal end of the second elongate member is located at the first point. The implant retaining portion is located proximal of the first point. The implant retaining portion comprises a space located between the elongate members and configured for receiving an implant portion, with the first elongate member on one side of the space and the second elongate member on another side. The implant retaining portion further comprises a proximal side and a distal side which further circumscribe the space. The proximal and distal sides are effective to prevent an implant received in the retaining portion from moving out of engagement with the retaining portion as the first elongate member is moved distally and proximally. The implant retaining portion is removable by withdrawing the second elongate member in a proximal direction with respect to the first elongate member, thereby moving the distal end of the elongate member proximally beyond the former location of the implant retaining portion. Associated methods, and other apparatus and methods, are also disclosed.

Priority: US20080139509P Applic. Date: 2008-12-19; US20090230252P Applic. Date: 2009-07-31; US20090249515P Applic. Date: 2009-10-07

Inventor: MIRIZZI MICHAEL S [US]


Application No.: US20100161032A1  Published: 24/Jun/2010

Title: BIOLOGICALLY ENGINEERED STENT

Applicant/Assignee:

Application No.: 12/733138   Filing Date: 14/Aug/2008

Abstract:Biologically engineered stents are provided, some having novel double-walled and hybrid composition constructions that are suitable for multi-drug delivery. Some embodiments of biologically engineered stents (BES) in accordance with the invention can deliver drugs in the form of gene therapy vectors to cells in the walls of stented vessels, thereby promoting local production of therapeutic factors that attract and enhance the formation of endothelium in the stented vessel. Other embodiments of BES include xenografts, allografts or isografts comprising sleeve-like natural matrices derived from vessels of animal and human subjects including postmortem human donors.

Priority: US20070956046P Applic. Date: 2007-08-15; WO2008US73145 Applic. Date: 2008-08-14

Inventor: AVELLANET FRANCISCO [US]


Application No.: US20100166857A1  Published: 01/Jul/2010

Title: PHARMACEUTICAL DOSAGE FORMS AND METHODS OF MANUFACTURING SAME

Applicant/Assignee:

Application No.: 12/649943   Filing Date: 30/Dec/2009

Abstract:The invention provides solid dispersions of at least one insoluble active pharmaceutical ingredient, pharmaceutical dosage forms comprising the solid dispersions, and methods of manufacturing same. In an embodiment, a solid dispersion of the present invention includes a plurality of coated particles comprising inert particles with a coating, wherein the coating comprises an insoluble active pharmaceutical ingredient dispersed in a hydrophilic polymer, and wherein the inert particles comprise nonpareils

and a plurality of granules comprising an insoluble active pharmaceutical ingredient with at least one pharmaceutically acceptable excipient. In an embodiment, the insoluble active pharmaceutical ingredient in the coating and the insoluble active pharmaceutical ingredient of the granules are the same type. A solid dispersion of the present invention may optionally be encapsulated in capsules or compressed into a tablet. Also disclosed are methods of making solid dispersions and methods of reducing plasma triglyceride and increasing high-density lipoprotein employing the solid dispersion.

Priority: US20080141472P Applic. Date: 2008-12-30

Inventor: YAN DONG [US]; SIEW LEE FOONG [US]; TING RICHARD [US]; CHEN TZU-YUAN [US]; PAWAR MAHENDRA SUDHAKAR [US]


Application No.: US20100167261A1  Published: 01/Jul/2010

Title: PLATELET STABILIZATION

Applicant/Assignee: SIEMENS HEALTHCARE DIAGNOSTICS INC

Application No.: 12/280027   Filing Date: 20/Feb/2007

Abstract:Provided are methods for stabilizing mean platelet component and/or platelets in a sample comprising combining said sample with EDTA, a second anticoagulant, and one or more kinase inhibitors. Also provided are compositions for stabilizing a sample comprising platelets, and kits for storing a platelet sample.

Priority: US20060775161P Applic. Date: 2006-02-21; WO2007US62408 Applic. Date: 2007-02-20

Inventor: JOU JOSEP MARIA [ES]; DIAZ-RICART MARIBEL [ES]; ESCOLAR GINES [ES]


Application No.: US20100168767A1  Published: 01/Jul/2010

Title: APPARATUS AND METHODS FOR DELIVERING HEMOSTATIC MATERIALS FOR BLOOD VESSEL CLOSURE

Applicant/Assignee: CARDIVA MEDICAL, INC

Application No.: 12/492779   Filing Date: 26/Jun/2009

Abstract:Apparatus for sealing a vascular wall penetration disposed at the end of the tissue tract comprises a shaft, an occlusion element, a hemostatic implant, and a protective sleeve. The apparatus is deployed through the tissue tract with the occlusion element temporarily occluding the vascular wall penetration and inhibiting backbleeding therethrough. The hemostatic implant, which will typically be a biodegradable polymer such as collagen carrying an anti-proliferative agent or coagulation promoter, will then be deployed from the sealing apparatus and left in place to enhance closure of the vascular wall penetration with minimum scarring. The implant may be radiopaque to allow observation before release.

Priority: US20080077104P Applic. Date: 2008-06-30

Inventor: YASSINZADEH ZIA [US]; PELAYO DELFIN [US]


Application No.: US20100172916A1  Published: 08/Jul/2010

Title: SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/614530   Filing Date: 09/Nov/2009

Abstract:The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080112788P Applic. Date: 2008-11-10

Inventor: GANT THOMAS G [US]; HODULIK CRAIG [US]; WOO SOON [US]


Application No.: US20100172998A1  Published: 08/Jul/2010

Title: PROCESS FOR PREPARING MICROPARTICLES THROUGH PHASE INVERSION PHENOMENA

Applicant/Assignee:

Application No.: 12/171275   Filing Date: 10/Jul/2008

Abstract:A process for preparing nanoparticles and microparticles is provided. The process involves forming a mixture of a polymer and a solvent, wherein the solvent is present in a continuous phase and introducing the mixture into an effective amount of a nonsolvent to cause the spontaneous formation of microparticles.

Priority: US2003-639770 Applic. Date: 2003-08-12; US2001-853329 Applic. Date: 2001-05-11; US1999-442723 Applic. Date: 1999-11-18; US1996-686928 Applic. Date: 1996-07-03; US19950001365P Applic. Date: 1995-07-21

Inventor: MATHIOWITZ EDITH [US]; CHICKERING III DONALD E [US]; JONG YONG S [US]; JACOB JULES S [US]


Application No.: US20100173402A1  Published: 08/Jul/2010

Title: Methods and Compositions for Isolating Metastatic Cancer Cells, and Use in Measuring Metastatic Potential of a Cancer Thereof

Applicant/Assignee: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK

Application No.: 12/725036   Filing Date: 16/Mar/2010

Abstract:The present invention relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. The invention further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the identification of agents having anti-metastatic potential. The present invention further provides methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipetidyl peptidase IV (DPPIV)] expressed on the surface of metastasizing cancer cells.

Priority: US2002-220347 Applic. Date: 2002-08-28; WO2001US26735 Applic. Date: 2001-08-28; US20000231517P Applic. Date: 2000-09-09

Inventor: CHEN WEN-TIEN [US]


Application No.: US20100179068A1  Published: 15/Jul/2010

Title: Assays

Applicant/Assignee: CLONDIAG GMBH

Application No.: 12/451243   Filing Date: 05/May/2008

Abstract:A method for assaying a sample for each of multiple analytes is described. The method includes contacting an array of spaced-apart test zones with a liquid sample (e.g., whole blood). The test zones disposed within a channel of a microfluidic device. The channel is defined by at least one flexible wall and a second wall which may or may not be flexible. Each test zone comprising a probe compound specific for a respective target analyte. The microfluidic device is compressed to reduce the thickness of the channel, which is the distance between the inner surfaces of the walls within the channel. The presence of each analyte is determined by optically detecting an interaction at each of multiple test zones for which the distance between the inner surfaces at the corresponding location is reduced. The interaction at each test zone is indicative of the presence in the sample of a target analyte.

Priority: US20070915884P Applic. Date: 2007-05-03; US20080036537P Applic. Date: 2008-03-14; WO2008EP55508 Applic. Date: 2008-05-05

Inventor: KAISER THOMAS [DE]; MOEBIUS KLAUS PETER [DE]; SCHULZ TORSTEN [DE]; UHLIG THOMAS [DE]; VON SCHENK ZU SCHWEINSBERG ALEXANDER [DE]; ERMANTRAUT EUGEN [DE]; TUCHSCHEERER JENS [DE]


Application No.: US20100183519A1  Published: 22/Jul/2010

Title: Topical Poloxamer Formulations for Enhancing Microvascular Flow: Compositions and Uses Thereof

Applicant/Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Application No.: 12/663583   Filing Date: 06/Jun/2008

Abstract:This invention relates to therapeutic compositions comprising a surface active copolymer, such as poloxamer-188, in an amount effective to enhance microvascular blood flow and/or inflammation in injured skin or other tissue, and methods of using the therapeutic compositions of the invention to inhibit decreased blood flow associated with an injury, disease, or disorder.

Priority: US20070933902P Applic. Date: 2007-06-08; WO2008US66094 Applic. Date: 2008-06-06

Inventor: KATZ ADAM J [US]; RODEHEAVER GEORGE T [US]


Application No.: US20100184069A1  Published: 22/Jul/2010

Title: PRESERVATION OF FETAL NUCLEIC ACIDS IN MATERNAL PLASMA

Applicant/Assignee: STRECK, INC

Application No.: 12/689370   Filing Date: 19/Jan/2010

Abstract:A method for preserving and processing fetal nucleic acids located within maternal plasma is disclosed, wherein a sample of maternal blood containing fetal nucleic acids is treated to reduce both cell lysis of the maternal blood cells and deoxyribonuclease (DNase) and ribonuclease (RNase) activity within the fetal nucleic acids. The treatment of the sample aids in increasing the amount of fetal nucleic acids that can be identified and tested while maintaining the structure and integrity of the fetal nucleic acids.

Priority: US20090146065P Applic. Date: 2009-01-21; US20090227529P Applic. Date: 2009-07-22

Inventor: FERNANDO M ROHAN [US]; CHEN KATE CHAO-WEI [US]


Application No.: US20100184084A1  Published: 22/Jul/2010

Title: METHODS FOR MEASURING PLATELET REACTIVITY OF INDIVIDUALS TREATED WITH DRUG ELUTING STENTS

Applicant/Assignee:

Application No.: 12/598581   Filing Date: 01/May/2008

Abstract:A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.

Priority: US2007-742684 Applic. Date: 2007-05-01; US2004-886155 Applic. Date: 2004-07-06; US20030485703P Applic. Date: 2003-07-08; WO2008US62297 Applic. Date: 2008-05-01

Inventor: COLLER BARRY [US]; DURBIN DENNIS [US]


Application No.: US20100184672A1  Published: 22/Jul/2010

Title: PROTEIN C FOR USE IN MAINTAINING HEMOSTASIS

Applicant/Assignee:

Application No.: 12/665540   Filing Date: 18/Jun/2008

Abstract:It is disclosed herein that protein C functions as a hemostatic agent. Thus, provided is a method of preventing, treating or ameliorating abnormal bleeding in a subject, comprising administering to the subject a protein C polypeptide or polynucleotide. Abnormal bleeding can result from a bleeding disorder, such as hemophilia or a platelet disorder, or from a bleeding episode, such as from a traumatic injury.

Priority: US20070944693P Applic. Date: 2007-06-18; WO2008US67321 Applic. Date: 2008-06-18

Inventor: MCCARTY OWEN J T [US]; GRUBER ANDRAS [US]; GRIFFIN JOHN H [US]


Application No.: US20100184781A1  Published: 22/Jul/2010

Title: FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

Applicant/Assignee: LEGOCHEM BIOSCIENCE LTD

Application No.: 12/598010   Filing Date: 09/May/2008

Abstract:The present invention relates to novel oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof, and processes for preparing the same, and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof can be usefully employed as an anticoagulant for treating thromboembolism and tumors via inhibition of coagulation factor Xa.

Priority: KR20070044980 Applic. Date: 2007-05-09; KR20080042740 Applic. Date: 2008-05-08; WO2008KR02619 Applic. Date: 2008-05-09

Inventor: CHO YOUNG LAG [KR]; SONG HO YOUNG [KR]; LEE DAE YON [KR]; BAEK SUNG YOON [KR]; CHAE SANG EUN [KR]; JO SANG HUI [KR]; KIM YEON OK [KR]; LEE HYANG SOOK [KR]; PARK JU HYUN [KR]; PARK TAE KYO [KR]; WOO SUNG HO [KR]; KIM YONG ZU [KR]


Application No.: US20100185134A1  Published: 22/Jul/2010

Title: Artifical Kidney

Applicant/Assignee: RELITECH B.V

Application No.: 12/664458   Filing Date: 16/Jun/2008

Abstract:Artificial kidney for gradual, and at least semi-continuous, blood treatment, wherein a blood stream is fed from a body of a living human or animal being into the artificial kidney, where anticoagulation is first effected, blood cells and molecules of large and medium molecular weight, such as proteins, are then primarily separated from plasma and fed back to the blood stream, regulating a water and salt balance by diverting excess plasma water and further removing from the blood stream, plasma or plasma water accumulated and toxic substances, by removal of specific electrolytes and waste products and wherein purified or partially purified plasma and plasma water is being carried back to the blood tract of the body.

Priority: EP20070110290 Applic. Date: 2007-06-14; WO2008NL50381 Applic. Date: 2008-06-16

Inventor: HOUWEN FRANCISCUS PETER [NL]; VAN MIDDENDORP HENK [NL]; MUSTERS JACOBUS CORNELIS [NL]


Application No.: US20100186099A1  Published: 22/Jul/2010

Title: Production of Human Glycosylated Proteins in Silk Worm

Applicant/Assignee:

Application No.: 12/627697   Filing Date: 30/Nov/2009

Abstract:A transgenic silkworm system for recombinant glycoprotein production is provided.

Priority: US2006-577528 Applic. Date: 2006-04-28; WO2004US35553 Applic. Date: 2004-10-28; US20030514741P Applic. Date: 2003-10-28

Inventor: FRASER MALCOM J [US]; JARVIS DONALD L [US]


Application No.: US20100192686A1  Published: 05/Aug/2010

Title: BLOOD TREATMENT SYSTEMS AND METHODS

Applicant/Assignee: DEKA PRODUCTS LIMITED PARTNERSHIP

Application No.: 12/549285   Filing Date: 27/Aug/2009

Abstract:Dialysis systems comprising actuators that cooperate to perform dialysis functions and sensors that cooperate to monitor dialysis functions are disclosed. According to one aspect, such a hemodialysis system comprises a user interface model layer, a therapy layer, below the user interface model layer, and a machine layer below the therapy layer. The user interface model layer is configured to manage the state of a graphical user interface and receive inputs from a graphical user interface. The therapy layer is configured to run state machines that generate therapy commands based at least in part on the inputs from the graphical user interface. The machine layer is configured to provide commands for the actuators based on the therapy commands.

Priority: US2008-199452 Applic. Date: 2008-08-27; US2008-072908 Applic. Date: 2008-02-27; US20070903582P Applic. Date: 2007-02-27; US20070904024P Applic. Date: 2007-02-27; US20080092239P Applic. Date: 2008-08-27

Inventor: KAMEN DEAN [US]; WILT MICHAEL J [US]; DEMERS JASON A [US]; BALLANTYNE TODD A [US]; GRAY LARRY B [US]; LEONARD SCOTT A [US]


Application No.: US20100196438A1  Published: 05/Aug/2010

Title: METHODS INCLUDING MEDICAL DEVICES HAVING A SURFACE INCLUDING A BIOLOGICALLY ACTIVE AGENT THEREIN

Applicant/Assignee: MEDTRONIC, INC

Application No.: 12/759110   Filing Date: 13/Apr/2010

Abstract:The present invention provides a medical device, and methods of preparing and using a medical device. The medical device has a surface including a biologically active agent therein. The methods are particularly useful for preparing, for example, coated stents having a biologically active agent within the coating.

Priority: US2005-138545 Applic. Date: 2005-05-26; US20040574739P Applic. Date: 2004-05-27

Inventor: DINH THOMAS Q [US]; PADUA RODOLFO [US]; CASAS-BEJAR JESUS [US]


Application No.: US20100196945A1  Published: 05/Aug/2010

Title: DEVICE AND METHOD FOR DETERMINING THE ERYTHROCYTE SEDIMENTATION RATE IN A BLOOD SAMPLE

Applicant/Assignee:

Application No.: 12/676308   Filing Date: 01/Sep/2008

Abstract:The invention discloses a blood analyzing device (100) comprising a holder (110) arranged for carrying a container (10) having a cuvette (20) containing a blood sample (30). The container (10) is positioned in the holder (110) so that a longitudinal axis (60) of the cuvette (20) is angled relative a horizontal axis (70). A light source (120) provides light (40) into the sample (30) and a detector (130) detects the output light (50) from a sub-portion of the blood sample (30). Kinetic information indicative of the change in hemoglobin concentration in a measuring volume (32, 34) is determined by a Hb processor (145) from the detected output light (50). An ESR processor (140) determines the erythrocyte sedimentation rate of the sample (30) based on the kinetic information.

Priority: SE20070002039 Applic. Date: 2007-09-04; WO2008SE50980 Applic. Date: 2008-09-01

Inventor: FORSELL TOMMY [SE]


Application No.: US20100200506A1  Published: 12/Aug/2010

Title: FLOW BALANCING AND SYNCHRONIZATION SYSTEM AND METHOD, ESPECIALLY FOR CITRATE

Applicant/Assignee: BAXTER INTERNATIONAL INC BAXTER HEALTHCARE S.A

Application No.: 12/763864   Filing Date: 20/Apr/2010

Abstract:A renal failure therapy system includes a blood pump

a citrate pump

and a control unit configured to automatically control the blood pump and the citrate pump to achieve a citrate flowrate that is based on a blood flowrate, so that the flowrates are synchronized.

Priority: US2006-356661 Applic. Date: 2006-02-16; US2003-685724 Applic. Date: 2003-10-15

Inventor: WARE LEE C [US]; BOEHNLEIN ARNOLD F [US]


Application No.: US20100203520A1  Published: 12/Aug/2010

Title: Method for the detection of gene transcripts in blood and uses thereof

Applicant/Assignee: GENENEWS, INC

Application No.: 12/587385   Filing Date: 05/Oct/2009

Abstract:The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20100204633A1  Published: 12/Aug/2010

Title: METHOD FOR VERIFYING AND/OR MONITORING THE CORRECT FUNCTION OF A SUPPLY DEVICE

Applicant/Assignee:

Application No.: 12/733702   Filing Date: 26/Aug/2008

Abstract:The present invention relates to a method for checking and/or monitoring the correct operation of an adding device of a medical apparatus, wherein the medical apparatus includes an extracorporeal circuit with which the adding device is connected such that an agent can be introduced into the extracorporeal circuit by means of the adding device, the pressure loss in the extracorporeal circuit being measured and evaluated for checking and/or monitoring the correct operation of the adding device. In accordance with the invention, the adding device for this purpose generates an oscillating pressure course.

Priority: DE200710044413 Applic. Date: 2007-09-18; WO2008EP06990 Applic. Date: 2008-08-26

Inventor: KOPPERSCHMIDT PASCAL [DE]


Application No.: US20100221756A1  Published: 02/Sep/2010

Title: ALLERGY TEST BASED ON FLOW CYTOMETRIC ANALYSIS

Applicant/Assignee: BUHLMANN LABORATORIES AG

Application No.: 12/677402   Filing Date: 11/Sep/2008

Abstract:The invention pertains to a method for the determination of basophil activation induced by a test substance by flow cytometric measurement of the changes of the mean or median fluorescence intensities (WI) of the basophilic Fc[epsilon]RI receptor present on the cell surface of basophils (MFI-Fc[epsilon]RI) and/or the IgE antibodies bound to the Fc[epsilon]RI receptor (MFI-IgE), and the CD63 antigen exposed on the cell surface of basophils after their activation (MFI-CD63), by means of a mixture of anti-CD63, anti-Fc[epsilon]RI or anti-IgE, and anti-CCR3 antibodies each labelled with a distinct fluorophore, of which at least one antibody acts as a basophil selection marker and at least two antibodies act as basophil activation markers, and bringing the mean fluorescence intensities of the activation markers in correlation to obtain an Activation Index. These methods combining the measurement of an early (such as IgE, Fc[epsilon]RI or CD203c) and a late basophil activation marker (such as CD63), respectively, provide a markedly improved clinical sensitivity in allergy diagnosis over existing methods which consider only one activation marker, such as CD203c or CD63, expressed in percentage of basophil activation. It is also an aspect of the present invention to provide an ex-vivo allergy provocation test comprising the above-mentioned flow cytometric measurement and analysis of the results as well as a test kit for carrying out the test in-vitro.

Priority: EP20070017775 Applic. Date: 2007-09-11; WO2008EP07494 Applic. Date: 2008-09-11

Inventor: SAINTE-LAUDY JEAN [FR]; SCHNEIDER MICHAEL [CH]; WEBER JAKOB [CH]


Application No.: US20100222723A1  Published: 02/Sep/2010

Title: Vibration method for clearing acute arterial thrombotic occlusions in the emergency treatment of heart attack and stroke

Applicant/Assignee: AHOF BIOPHYSICAL SYSTEMS INC

Application No.: 12/798437   Filing Date: 05/Apr/2010

Abstract:An emergency method of using localized mechanical percussion for enhancing clearance of potentially life threatening acute thrombotic arterial obstructions blocking blood flow to vital internal organs such as the heart or brain of a patient, comprising the step of applying non-invasive localized low frequency mechanical percussion at a frequency between 1 Hz-1000 Hz and a stroke or displacement amplitude in the range of 0.1-10 mm upon a targeted external body surface deemed generally proximate such acute thrombotic arterial obstruction, whereby said percussion accelerates the emergency clearance of the acute thrombotic arterial obstruction in restoration of blood flow to the vital internal organ. Preferred methods for percussion delivery to the chest wall/upper back or head/neck of a patient are described for use in treatment of heart attack or acute ischemic stroke respectively.

Priority: CA20032439667 Applic. Date: 2003-09-04; US2008-291128 Applic. Date: 2008-11-05; US2008-218054 Applic. Date: 2008-07-11; US2005-036386 Applic. Date: 2005-01-18; US2004-902122 Applic. Date: 2004-07-30

Inventor: HOFFMANN ANDREW KENNETH [CA]


Application No.: US20100226989A1  Published: 09/Sep/2010

Title: Nanoparticulate megestrol formulations

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LIMITED

Application No.: 11/472556   Filing Date: 22/Jun/2006

Abstract:The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.

Priority: US2005-093149 Applic. Date: 2005-03-30; US2003-412669 Applic. Date: 2003-04-14; US20050693127P Applic. Date: 2005-06-22; US20020371680P Applic. Date: 2002-04-12; US20020430348P Applic. Date: 2002-12-03

Inventor: HOVEY DOUGLAS [US]; PRUITT JOHN [US]; RYDE TUULA [US]


Application No.: US20100233296A1  Published: 16/Sep/2010

Title: METHOD AND SYSTEM FOR PRODUCING A SUBSTANCE OR A SIGNAL WITH A COAGULATING OR ANTICOAGULANT EFFECT

Applicant/Assignee: DIGIBIO

Application No.: 12/633271   Filing Date: 08/Dec/2009

Abstract:The invention concerns a method and a system for producing a signal, in particular an electric signal, or a substance having a coagulating or anticoagulant effect. The method is characterised in that it is based on a source substance with coagulating effect, in particular, Ca++ ions, or an anticoagulant affect, in particular heparin. The method consists in: transforming the electromagnetic field derived from said source substance located in the chamber, into a signal, in particular an electric signal, using a transducer-receiver sensing the electromagnetic field

applying to a receiving substance located in the chamber, in particular water or a water-ethanol mixture or homeopathic granules, said signal derived from said transducer-receiver, using a transducer-transmitter. After said treatment, the receiving substance, initially inactive, has a coagulating or anticoagulant effect.

Priority: FR19980012058 Applic. Date: 1998-09-23; FR19990002329 Applic. Date: 1999-02-22; US2001-787781 Applic. Date: 2001-05-24; WO1999FR02269 Applic. Date: 1999-09-23

Inventor: BENVENISTE JACQUES [FR]; BENVENISTE LAURENT [FR]; GUILLONNET DIDIER [FR]


Application No.: US20100234291A1  Published: 06/May/2010

Title: PREPARATION OF LOW BLEEDING ANTICOAGULANT FUSION PROTEIN AND ITS USE

Applicant/Assignee: BEIJING SANLY SCI-TECH DEVELOP INC. LTD INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA

Application No.: 12/519309   Filing Date: 11/Dec/2007

Abstract:Provided is an anticoagulant fusion protein comprising oligopeptide recognizable and cleavable by either factor XIa and factor Xa or thrombin and factor Xa. Also provided are the preparation method of the anticoagulant fusion protein and medicinal use thereof.

Priority: CN20061165756 Applic. Date: 2006-12-15; WO2007CN03526 Applic. Date: 2007-12-11

Inventor: WU ZUZE [CN]; YU AIPING [CN]; ZHANG CHUANLING [CN]; TANG ZHONGXIONG [CN]


Application No.: US20100234788A1  Published: 16/Sep/2010

Title: System and Method for the Re-Anticoagulation of Platelet Rich Plasma

Applicant/Assignee: HAEMONETICS CORPORATION

Application No.: 12/402565   Filing Date: 12/Mar/2009

Abstract:A method for the re-anticoagulation of platelet rich plasma in a blood apheresis system includes priming the blood apheresis system with anticoagulant, such that a volume of anticoagulant is transferred to a PRP container. The method may then transfer the anticoagulant within the PRP container to a red blood cell container, and collect a volume of platelet rich plasma within the PRP container. The platelet rich plasma may be collected in a plurality of cycles. Between collection cycles, the method may transfer a portion of the volume of anticoagulant from the red blood cell container to the PRP container.

Priority:

Inventor: PAGES ETIENNE [FR]; RAGUSA MICHAEL [US]


Application No.: US20100239673A1  Published: 23/Sep/2010

Title: Blood compatible nanomaterials and methods of making and using the same

Applicant/Assignee:

Application No.: 11/497838   Filing Date: 01/Aug/2006

Abstract:The invention provides blood compatible nanomaterials, biomaterials prepared therewith and blood compatible medical devices fabricated using the biomaterials of the invention. The invention further provides methods of making and using the nanomaterials, biomaterials and medical devices of the invention for the diagnosis, prevention and treatment of medical conditions. The invention further provides methods of using room temperature ionic liquids to make blood compatible nanomaterials.

Priority: US20050704383P Applic. Date: 2005-08-01; US20050704384P Applic. Date: 2005-08-01

Inventor: LINHARDT ROBERT J [US]; MURUGESAN SARAVANABABU [US]; PARK TAEJOON [US]


Application No.: US20100240584A1  Published: 23/Sep/2010

Title: Nematode-extracted serine protease inhibitors and anticoagulant proteins

Applicant/Assignee:

Application No.: 12/290059   Filing Date: 27/Oct/2008

Abstract:Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA, expression systems.

Priority: US2006-454308 Applic. Date: 2006-06-14; US2005-092336 Applic. Date: 2005-03-29; US2000-498272 Applic. Date: 2000-02-04; US2000-498556 Applic. Date: 2000-02-04; US1999-249472 Applic. Date: 1999-02-12; US1999-249451 Applic. Date: 1999-02-12; US1999-249473 Applic. Date: 1999-02-12; US1999-249448 Applic. Date: 1999-02-12; US1999-249461 Applic. Date: 1999-02-12; US1999-249471 Applic. Date: 1999-02-12; US1997-809455 Applic. Date: 1997-11-24; WO1995US13231 Applic. Date: 1995-10-17; US1995-461965 Applic. Date: 1995-06-05; US1995-465380 Applic. Date: 1995-06-05; US1995-486397 Applic. Date: 1995-06-05; US1995-486399 Applic. Date: 1995-06-05; US1994-326110 Applic. Date: 1994-10-18

Inventor: VLASUK GEORGE PHILLIP [US]; STANSSENS PATRICK ERIC HUGO [BE]; MESSENS JORIS HILDA LIEVEN [BE]; LAUWEREYS MARC JOSEF [BE]; LAROCHE YVES RENE [BE]; JESPERS LAURENT STEPHANE [BE]; JOZEF GANSEMANS YANNICK GEORGES [BE]; MOYLE MATTHEW [US]; BERGUM PETER W [US]


Application No.: US20100240602A1  Published: 23/Sep/2010

Title: METHODS AND COMPOSITIONS FOR OPTIMIZING BLOOD AND TISSUE STABILITY OF CAMPTOTHECIN AND OTHER ALBUMIN-BINDING THERAPEUTIC COMPOUNDS

Applicant/Assignee:

Application No.: 12/755001   Filing Date: 06/Apr/2010

Abstract:The present invention provides methods and formulations for optimizing the anti-cancer and anti-HIV activities of a camptothecin drug, including camptothecin and its related analogs including 9-aminocamptothecin and 9-nitrocamptothecin. The invention involves methodologies and formulations that limit human serum albumin-mediated reduction of the anti-cancer and anti-HIV effects of the camptothecins, and the methods and formulations provide combination therapies in which binding of the camptothecin agent to human serum albumin can be modulated by the administration of a competing agent such as ibuprofen, clofibrate or clofibric acid that also binds human serum albumin. Reduced camptothecin drug binding to human serum albumin can result in elevated camptothecin free drug levels and thus improve the effectiveness of treatment regimens involving these drugs. Further agents such as methotrexate and AZT can also be used in cancer and HIV-positive patients employing camptothecin drugs.

Priority: US2002-101513 Applic. Date: 2002-03-20; US20010276908P Applic. Date: 2001-03-20

Inventor: BURKE THOMAS G [US]; CARTER DANIEL C [US]


Application No.: US20100247492A1  Published: 30/Sep/2010

Title: METHODS FOR THE DETECTION OF CIRCULATING TUMOR CELLS

Applicant/Assignee: THE SCRIPPS RESEARCH INSTITUTE

Application No.: 12/553733   Filing Date: 03/Sep/2009

Abstract:The present invention provides methods for revealing, detecting, and analyzing circulating tumor cells in the blood of a subject. Revealing detectable circulating tumor cells allows for early stage detection and diagnosis in addition to long term prognosis in subjects with cancer. Additionally, enrichment allows for robust detection and clinically meaningful analysis of low volume samples for use in clinical settings as well as innovative methods for the treatment of cancers.

Priority: US20080094819P Applic. Date: 2008-09-05

Inventor: KUHN PETER [US]; GRIFFIN JOHN H [US]; BETHEL KELLY [US]; MARRINUCCI DENA [US]


Application No.: US20100252452A1  Published: 07/Oct/2010

Title: APPARATUS AND METHOD FOR ELECTROCHEMICAL DETECTION

Applicant/Assignee: UNIVERSAL BIOSENSORS PTY LTD

Application No.: 12/739948   Filing Date: 25/Oct/2008

Abstract:The present invention is directed to a sensor with opposing electrodes and test strips using this sensor. The invention can be used to measure blood or plasma coagulation in assays like prothrombin time (PT) and thrombin potential, for example, in point-of-care monitoring of anticoagulants.

Priority: US20070983029P Applic. Date: 2007-10-26; WO2008IB02849 Applic. Date: 2008-10-25

Inventor: NEWMAN PETER MICHAEL [AU]; HODGES ALASTAIR M [AU]


Application No.: US20100255050A1  Published: 07/Oct/2010

Title: Polyethylene Based Bioactive Agents

Applicant/Assignee:

Application No.: 12/664172   Filing Date: 24/Jul/2008

Abstract:The present invention concerns an acyclic diene metathesis (ADMET) chemistry-based method of making polymers incorporating biologically active molecules, and the polymers formed thereby. Functionalized polymers prepared by this method can be used to produce a broad range of commercially important products such as drag delivery agents (prodrugs), chromatography reagents (e.g., for use in separatory reagents), biomimetics, and biodegradable synthetic polymers.

Priority: US20070951666P Applic. Date: 2007-07-24; WO2008US71020 Applic. Date: 2008-07-24

Inventor: LEONARD JAMES KLEIN [US]; WAGENER KENNETH BOONE [US]


Application No.: US20100255102A1  Published: 07/Oct/2010

Title: STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED ELAN PHARMA INTERNATIONAL, LTD

Application No.: 10/851661   Filing Date: 24/May/2004

Abstract:The present invention relates to methods for sterilization of dispersions of one or more nanoparticulate active agents via gamma irradiation.

Priority: US20030472434P Applic. Date: 2003-05-22

Inventor: BOSCH H WILLIAM [US]; KELLER JANINE [US]


Application No.: US20100256589A1  Published: 07/Oct/2010

Title: Transparent Multilayer Injection-Moulded Container Having A Fluoropolymer Barrier Layer

Applicant/Assignee:

Application No.: 12/744401   Filing Date: 10/Nov/2008

Abstract:The injection-moulded multilayer transparent plastic container (1) exhibits air and water barrier properties, and has at least one barrier layer (CL) comprising a fluoropolymer. Preferably, said fluoropolymer is a homo or copolymer of polychlorotrifluoroethylene (PCTFE).

Priority: EP20070022924 Applic. Date: 2007-11-27; WO2008EP09457 Applic. Date: 2008-11-10

Inventor: DEGROOTE LAURENT [FR]


Application No.: US20100260828A1  Published: 14/Oct/2010

Title: Modulation of Platelet Aggregation

Applicant/Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

Application No.: 12/611446   Filing Date: 03/Nov/2009

Abstract:Methods and compositions for inhibition of platelet cell aggregation are described. In particular, compositions comprising cell permeant RGT peptides, such as RGT bound to a lipid moiety are provided. Compositions may be used in the treatment and prevention of clot related diseases such as stroke and myocardial infarction.

Priority: US20080110740P Applic. Date: 2008-11-03

Inventor: DU XIAOPING [US]; XI XIAODONG [CN]


Application No.: US20100261203A1  Published: 14/Oct/2010

Title: Methods and kits for screening transplant recipients and candidates

Applicant/Assignee: NATIONAL INSTITUTE OF TRANSPLANTATION FOUNDATION

Application No.: 12/755843   Filing Date: 07/Apr/2010

Abstract:Methods and kits are provided for determining of immunoglobulin isotypes and subclasses in a subject. In general the subject is a human who is a transplant candidate recipient or recipient, has allergies, or has an autoimmune disease. The method involves analyzing a sample of a body fluid of a transplant candidate or recipient, allergy patient or autoimmune disease sufferer and correlating the relative amounts of each immunoglobulin isotype and subtype, such that the distribution of isotypes and subtypes is an indication of success of the transplant in the candidate and recipient or the prognosis of the autoimmune disease.

Priority: US20090167365P Applic. Date: 2009-04-07

Inventor: CICCIARELLI JAMES C [US]; KASAHARA NORIYUKI [US]


Application No.: US20100267063A1  Published: 21/Oct/2010

Title: METHODS AND APPARATUSES FOR CONDUCTING ASSAYS

Applicant/Assignee: MESO SCALE TECHNOLOGIES, LLC

Application No.: 12/831139   Filing Date: 06/Jul/2010

Abstract:Disclosed are methods for conducting assays of samples, such as whole blood, that may contain cells or other particulate matter. Also disclosed are systems, devices, equipment, kits and reagents for use in such methods. One advantage of certain disclosed methods and systems is the ability to rapidly measure the concentration of an analyte of interest in blood plasma from a whole blood sample without blood separation and hematocrit correction.

Priority: US2005-145528 Applic. Date: 2005-06-03; US20040576710P Applic. Date: 2004-06-03

Inventor: BILLADEAU MARK A [US]; DEBAD JEFF D [US]; GLEZER ELI N [US]; LELAND JONATHAN K [US]; WIJAYAWARDHANA CHARLES A [DE]


Application No.: US20100267582A1  Published: 21/Oct/2010

Title: DIFFERENTIAL EXPRESSION OF MOLECULES ASSOCIATED WITH ACUTE STROKE

Applicant/Assignee: THE GOVERNMENT OF THE UNITED STATES OF AMERICA ASREPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

Application No.: 12/829229   Filing Date: 01/Jul/2010

Abstract:Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely neurological recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment. Also provided are methods of identifying one or more agents that alter the activity (such as the expression) of an ischemic stroke-related molecule.

Priority: US2005-155835 Applic. Date: 2005-06-17; WO2005US18744 Applic. Date: 2005-05-27; US20040575279P Applic. Date: 2004-05-27

Inventor: BAIRD ALISON E [US]; MOORE DAVID F [US]; GOLDIN EHUD [US]


Application No.: US20100272639A1  Published: 28/Oct/2010

Title: POLYSACCHARIDE NANOPARTICLES

Applicant/Assignee:

Application No.: 12/809629   Filing Date: 19/Dec/2008

Abstract:Polysaccharide nanoparticles that are particularly useful in for example drug and agent delivery, tissue-specific targeting, for medical imaging and diagnosis, as well as modifiers of physico-chemical properties. The nanoparticles can be highly-branched glucose homopolymers and can be characterized by a uniform spherical shape. They are monodisperse, hydrophilic and produce low solution viscosities. The nanoparticles are non-toxic, biocompatible and biodegradable. Also, the process of isolation of said polysaccharide nanoparticles from various organisms including, but not limited to, microorganisms such as bacteria and yeasts. Also provided are methods for chemical conjugation of the polysaccharide nanoparticles with various agents. Also provided are examples of use of the polysaccharide nanoparticles and their derivatives as drug delivery systems and fluorescent di-agnostics.

Priority: US20070016418P Applic. Date: 2007-12-21; WO2008IB03958 Applic. Date: 2008-12-19

Inventor: DUTCHER JOHN ROBERT [CA]


Application No.: US20100272694A1  Published: 28/Oct/2010

Title: CLINIC COMPLIANT METHOD FOR BANKING HUMAN PLACENTAL MESENCHYMAL CELLS

Applicant/Assignee: AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY

Application No.: 12/747307   Filing Date: 17/Oct/2008

Abstract:The present invention relates to a method for processing human placental cell sample, a human placental cell sample obtained according to said method for processing human placental cell sample, a human placental cell bank, a method for banking human placental cells, a method for searching human placental cell sample in said human placental cell bank according to the present invention, a method for preparing human cord blood serum, use of human placental cells obtained by said method for processing human placental cell sample or human placental cell bank established by said method for banking human placental cells in treating human dysfunction and diseases due to cell injury or cell malfunction, as well as a method for treating human dysfunction and diseases due to cell injury or cell malfunction.

Priority: WO2008CN01756 Applic. Date: 2008-10-17

Inventor: YANG YINXUE [CN]; WEI JUN [CN]; LI YUKUI [CN]; WANG LIBIN [CN]; LIU TING [CN]; MA XIAONA [CN]; ZHANG GUANGYI [CN]


Application No.: US20100273206A1  Published: 28/Oct/2010

Title: DIAGNOSTIC IN VITRO METHOD FOR ASSESSING VON WILLEBRAND DISEASE AND INCREASED BLEEDING RISK ASSOCIATED WITH VON WILLEBRAND DISEASE AND ACQUIRED OR CONGENITAL DISORDERS OF PLATELET FUNCTION

Applicant/Assignee:

Application No.: 12/809977   Filing Date: 18/Dec/2008

Abstract:The invention relates to an in-vitro method for diagnosing Von Willebrand Disease (VWD) and an increased bleeding risk associated with Von Willebrand Disease and/or acquired or congenital platelet function defects that reduce the interactions of Von Willebrand Factor (VWF) with platelets. The in-vitro method of the invention may also be used to diagnose further bleeding risks. The test is suitable for use as a screening test based on whole blood and has the additional benefit of being suitable as a point of care test. The method involves the incubation of a sample containing platelets and hemostasis factors with an activator of platelet aggregation and the measurement of the viscoelastic change after inducing coagulation, e.g., by means of thromboelastography (TEG).

Priority: EP20070024932 Applic. Date: 2007-12-21; EP20080105554 Applic. Date: 2008-10-10; WO2008EP10899 Applic. Date: 2008-12-19

Inventor: RAUH MANFRED [DE]; TOPF HANS-GEORG [DE]


Application No.: US20100274168A1  Published: 28/Oct/2010

Title: EXTERNAL FUNCTIONAL MEANS, BLOOD TREATMENT APPARATUS FOR RECEIVING AN EXTERNAL FUNCTIONAL MEANS IN ACCORDANCE WITH THE INVENTION, AND METHOD

Applicant/Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

Application No.: 12/766424   Filing Date: 23/Apr/2010

Abstract:An external functional means comprises at least one housing body, at least one chamber integrated into the housing body for receiving medical fluids, at least one passage integrated into the housing body for receiving and/or conducting a medical fluid, and at least one valve means completely or partly integrated into the housing body for controlling or regulating a fluid flowing through the external functional means. The invention further specifies a blood treatment apparatus and methods which may be carried out by means of the external functional means of the invention and by means of the blood treatment apparatus, respectively.

Priority: DE200910018664 Applic. Date: 2009-04-23; DE200910024468 Applic. Date: 2009-06-10; US20090185643P Applic. Date: 2009-06-10

Inventor: GRONAU SOEREN [DE]; GUENTHER GOETZ [DE]; HAECKER JUERGEN [DE]; LAUER MARTIN [DE]; MANKE JOACHIM [DE]; NIKOLIC DEJAN [DE]; WEIS MANFRED [DE]


Application No.: US20100278893A1  Published: 04/Nov/2010

Title: IMPLANTABLE MATERIAL COMPRISING CELLULOSE AND THE GLYCOPEPTIDE XYLOGLUCAN-GRGDS

Applicant/Assignee: SWE TREE TECHNOLOGIES AB

Application No.: 12/528800   Filing Date: 26/Feb/2008

Abstract:Implantable materials for medical or surgical applications comprising specific chemical groups on their surface to alter the physico-chemical properties of said material rendering it suitable implantation or biocompatible properties.

Priority: EP20070103055 Applic. Date: 2007-02-26; US20070891536P Applic. Date: 2007-02-26; WO2008EP52286 Applic. Date: 2008-02-26

Inventor: BODIN AASE [SE]; GATENHOLM PAUL [SE]; FINK HELEN [SE]; RISBERG BO [SE]; BRUMER HARRY [SE]; AHRENSTEDT NILS LAGE [SE]


Application No.: US20100280414A1  Published: 04/Nov/2010

Title: Protease Inhibitor Sample Collection System

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 12/629158   Filing Date: 02/Dec/2009

Abstract:A collection container and a method for collecting a biological sample, particularly whole blood, includes at least one stabilizing agent in an amount effective to stabilize and inhibit protein degradation and/or fragmentation. The stabilizing agent is able to stabilize proteases in the biological sample, particularly at the point of collection, by inhibiting protein degradation and/or fragmentation in the sample when the sample is stored. The stabilizing agent comprises or consists of one or more protease inhibitors.

Priority: US2007-937954 Applic. Date: 2007-11-09; US2003-436263 Applic. Date: 2003-05-13; US20020379399P Applic. Date: 2002-05-13

Inventor: HAYWOOD BRUCE [US]; DASTANE AJIT [US]; LIN FU-CHUNG [US]


Application No.: US20100285044A1  Published: 11/Nov/2010

Title: METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS

Applicant/Assignee:

Application No.: 12/685307   Filing Date: 11/Jan/2010

Abstract:A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

Priority: US2000-699003 Applic. Date: 2000-10-26; US1999-316226 Applic. Date: 1999-05-21; US1998-083307 Applic. Date: 1998-05-22

Inventor: LENTZ M RIGDON [US]


Application No.: US20100285560A1  Published: 11/Nov/2010

Title: RETICULOCYTE MIMETICS AND METHOD OF PREPARATION OF THE SAME

Applicant/Assignee: SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD

Application No.: 12/774442   Filing Date: 05/May/2010

Abstract:In one aspect of the present disclosure there is provided a method for preparing reticulocyte mimetics. In another aspect of the present disclosure there are provided reticulocyte mimetics obtained using the method. In yet another aspect of the present disclosure there is provided a whole blood reference control including the reticulocyte mimetics as provided. In still another aspect of the present disclosure there is provided a composition useful for preparing reticulocyte mimetics.

Priority: CN20091107227 Applic. Date: 2009-05-06

Inventor: WANG LU [CN]; XU ZUYUE [CN]; XIA TAO [CN]


Application No.: US20100288706A1  Published: 18/Nov/2010

Title: METHOD FOR THE PREPARATION OF AT LEAST ONE COMPOUND FROM BLOOD, AND EXTRACTION DEVICE FOR USE IN THE EXECUTION OF SAID METHOD

Applicant/Assignee: BIOTECHNOLOGY INSTITUTE, I MAS D, S.L,

Application No.: 12/780287   Filing Date: 14/May/2010

Abstract:Method for the preparation of at least one compound with biological properties from blood, where said method is performed in sealed tubes at a pressure below atmospheric pressure, thereby reducing or preventing the bacterial contamination of the compound through handling. The method comprises the repetition, for as many times as is required, of the following steps: connecting a second container that is vacuum-sealed to an extraction device connected in turn to a first container that contains blood separated into fractions, waiting for a period of time until the required fraction(s) is/are transferred, and removing said second container, with it thus being possible to obtain several second containers with different compounds for different medical applications including biological therapies. The steps may be performed in a closed system, without removing the caps of the containers, or alternatively the first container may be opened prior to the introduction of the extraction device.

Priority: ES20090001227 Applic. Date: 2009-05-14; ES20100000306 Applic. Date: 2010-03-10

Inventor: ALDECOA EDUARDO ANITUA [ES]


Application No.: US20100292268A1  Published: 18/Nov/2010

Title: Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use

Applicant/Assignee: CYDEX PHARMACEUTICALS, INC

Application No.: 12/597908   Filing Date: 26/Apr/2008

Abstract:The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD.

Priority: US20070914555P Applic. Date: 2007-04-27; WO2008US61697 Applic. Date: 2008-04-26

Inventor: MOSHER JERRY L [US]; WEDEL REBECCA L [US]; JOHNSON KAREN T [US]; MACHATHA STEPHEN G [US]; COWEE JANE A [US]; CUSHING DANIEL J [US]


Application No.: US20100297211A1  Published: 25/Nov/2010

Title: BIOBENEFICIAL POLYAMIDE/POLYETHYLENE GLYCOL POLYMERS FOR USE WITH DRUG ELUTING STENTS

Applicant/Assignee:

Application No.: 12/845385   Filing Date: 28/Jul/2010

Abstract:This disclosure provides a medical device and a method of forming the medical device. The medical device comprises a coating comprising a type-one polymer and a type-two polymer. The type-one polymer comprises at least two different blocks, at least one L1 block with the formula and at least one L2 block with the formula Medical devices comprising these polymers, mixtures of these polymers with therapeutic agents, and methods of making these polymers and mixtures are within the scope of this disclosure.

Priority: US2008-207419 Applic. Date: 2008-09-09; US2003-741214 Applic. Date: 2003-12-19

Inventor: PACETTI STEPHEN D [US]


Application No.: US20100298529A1  Published: 25/Nov/2010

Title: MANUFACTURE AND USE OF MODIFIED POLYSACCHARIDE CHITOSAN BONDS AND A PROCESS TO IMPROVE THE PREPARATION OF HES-MEDICINAL SUBSTANCE COMPOUNDS

Applicant/Assignee:

Application No.: 12/293784   Filing Date: 26/Apr/2007

Abstract:The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.

Priority: DE200610020035 Applic. Date: 2006-04-26; WO2007EP54124 Applic. Date: 2007-04-26

Inventor: MEIER BERND HORST [DE]; MEIER NELE [DE]


Application No.: US20100303882A1  Published: 02/Dec/2010

Title: Medical Devices for Localized Drug Delivery

Applicant/Assignee: MALLINCKRODT INC

Application No.: 12/472398   Filing Date: 27/May/2009

Abstract:In certain embodiments, the invention relates to an implantable medical device that includes a body having an internal cavity. Receptor sites in the internal cavity may be adapted to repeatedly bind to, temporarily hold, and release an active agent. An opening may extend through the body and into the internal cavity to allow the active agent into and out of the internal cavity. This opening may be sized and shaped to prevent blood cells from entering the internal cavity through the opening while allowing the active agent to enter and/or exit the cavity via the opening. A polymeric structure may be located in the internal cavity. This polymeric structure may include artificial receptor site mimics for the active agent.

Priority: US2009-516236 Applic. Date: 2009-05-26

Inventor: CANTRELL GARY L [US]; BERBERICH DAVID W [US]


Application No.: US20100305688A1  Published: 02/Dec/2010

Title: Medical Devices for Localized Drug Delivery

Applicant/Assignee: MALLINCKRODT INC

Application No.: 12/472785   Filing Date: 27/May/2009

Abstract:In certain embodiments, the invention relates to an implantable medical device that includes a body having an internal cavity. Receptor sites in the internal cavity may be adapted to repeatedly bind to, temporarily hold, and release an active agent. An opening may extend through the body and into the internal cavity to allow the active agent into and out of the internal cavity. This opening may be sized and shaped to prevent blood cells from entering the internal cavity through the opening while allowing the active agent to enter and/or exit the cavity via the opening. A polymeric structure may be located in the internal cavity. This polymeric structure may include artificial receptor site mimics for the active agent.

Priority: US2009-472398 Applic. Date: 2009-05-27; US2009-516236 Applic. Date: 2009-05-26

Inventor: CANTRELL GARY L [US]; BERBERICH DAVID W [US]


Application No.: US20100310646A1  Published: 09/Dec/2010

Title: SELECTIVE EXOSITE INHIBITION OF PAPP-A ACTIVITY AGAINST IGFBP-4

Applicant/Assignee:

Application No.: 12/864604   Filing Date: 23/Jan/2009

Abstract:The present invention relates in one embodiment to PAPP-A exosite(s) interactors such as antibodies which bind to a region comprising LNR3 of PAPP-A and efficiently inhibit proteolysis of IGFBP-4, but not -5. The region comprising LNR3 represents a substrate binding exosite, which can be targeted for selective proteolytic inhibition. Accordingly, the present invention relates in one embodiment to differential inhibition of natural protease substrates by exosite targeting.

Priority: DK20080000148 Applic. Date: 2008-02-01; US20080023631P Applic. Date: 2008-01-25; US20080025545P Applic. Date: 2008-02-01; WO2009EP50796 Applic. Date: 2009-01-23

Inventor: OXVIG CLAUS [DK]; MIKKELSEN JAKOB HAUGE [DK]; NIELSEN CLAUS GYRUP [DK]


Application No.: US20100315231A1  Published: 16/Dec/2010

Title: DEVICE FOR THE TREATMENT AND EXTRACORPOREAL CIRCULATION OF BLOOD OR BLOOD COMPONENTS

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 12/809032   Filing Date: 04/Aug/2008

Abstract:The invention relates to a medical device for providing a plurality of extracorporeal blood or plasma treatments, apt to receive at least one disposable article that can be connected to extracorporeal circuit, each disposable article being equipped with storage means containing information about the disposable article, the device comprising a first receiving station (2) for disposable articles (100) with a first reading means (3) for the associated article, a second receiving station (3) for disposable articles (100) with a second reading means (3) for the associated article, a memory comprising information concerning at least one treatment protocol designed to be executed by the device, and information concerning a configuration of the disposable articles necessary for each treatment protocol at each receiving station, a control unit (10)

for comparing the stored configuration of articles concerning a treatment protocol with the configuration of articles once it is installed.

Priority: FR20070008917 Applic. Date: 2007-12-20; WO2008IB02033 Applic. Date: 2008-08-04

Inventor: RADA HIRAM [FR]


Application No.: US20100316651A1  Published: 16/Dec/2010

Title: CARDIOVASCULAR RELATED USES OF IL-1BETA ANTIBODIES AND BINDING FRAGMENTS THEREOF

Applicant/Assignee: XOMA TECHNOLOGY LTD

Application No.: 12/790738   Filing Date: 28/May/2010

Abstract:Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1[beta] binding molecules (e.g., IL-1[beta] binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease.

Priority: US20100313001P Applic. Date: 2010-03-11; US20090252571P Applic. Date: 2009-10-16; US20090182679P Applic. Date: 2009-05-29

Inventor: SCANNON PATRICK J [US]; SOLINGER ALAN M [US]; FELDSTEIN JEFFREY D [US]


Application No.: US20100322852A1  Published: 23/Dec/2010

Title: NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 12/870722   Filing Date: 27/Aug/2010

Abstract:Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2007-928278 Applic. Date: 2007-10-30; US2003-392403 Applic. Date: 2003-03-20; US2010-729018 Applic. Date: 2010-03-22; US2007-650412 Applic. Date: 2007-01-08; US2002-323736 Applic. Date: 2002-12-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21; US20020366542P Applic. Date: 2002-03-25; US20020365540P Applic. Date: 2002-03-20

Inventor: MERISKO-LIVERSIDGE ELAINE [US]; BOSCH H WILLIAM [US]; CARY GRETA G [US]; PRUITT JOHN [US]; RYDE TUULA [US]; JAIN RAJEEV [US]; WALTERS AMY [US]


Application No.: US20100322853A1  Published: 23/Dec/2010

Title: NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 12/870745   Filing Date: 27/Aug/2010

Abstract:Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2007-928289 Applic. Date: 2007-10-30; US2003-392403 Applic. Date: 2003-03-20; US2010-729018 Applic. Date: 2010-03-22; US2007-650412 Applic. Date: 2007-01-08; US2002-323736 Applic. Date: 2002-12-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21; US20020366542P Applic. Date: 2002-03-25; US20020365540P Applic. Date: 2002-03-20

Inventor: MERISKO-LIVERSIDGE ELAINE [US]; BOSCH H WILLIAM [US]; CARY GRETA G [US]; PRUITT JOHN [US]; RYDE TUULA [US]; JAIN RAJEEV [US]; WALTERS AMY [US]


Application No.: US20100322869A1  Published: 23/Dec/2010

Title: METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED SAFETY PROFILE OVER CONVENTIONAL WARFARIN THERAPY

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/817347   Filing Date: 17/Jun/2010

Abstract:A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

Priority: WO2009EP64873 Applic. Date: 2009-11-10; US20090237552P Applic. Date: 2009-08-27; US20080113404P Applic. Date: 2008-11-11

Inventor: REILLY PAUL ANTHONY [US]


Application No.: US20100322870A1  Published: 23/Dec/2010

Title: METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/817369   Filing Date: 17/Jun/2010

Abstract:A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient 150 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

Priority: WO2009EP64874 Applic. Date: 2009-11-10; US20090237559P Applic. Date: 2009-08-27; US20080113413P Applic. Date: 2008-11-11

Inventor: REILLY PAUL ANTHONY [US]


Application No.: US20100322997A1  Published: 23/Dec/2010

Title: METHOD FOR PRODUCING BIOLOGICALLY INGESTIBLE MICROPARTICLES, BIOLOGICALLY INGESTIBLE MICROPARTICLES, AND DISPERSION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Applicant/Assignee: M. TECHNIQUE CO., LTD

Application No.: 12/668021   Filing Date: 04/Jul/2008

Abstract:A method of separating biologically ingestible microparticles is used to obtain biologically ingestible microparticles in a thin film fluid formed between two processing surfaces provided with a solution containing a first solvent in which an objective substance to be pulverized is dissolved and a solvent capable of serving as a second solvent in which the solubility of the microparticles is lower than in the first solvent, the two processing surfaces being arranged so as to be able to approach to and separate from each other, at least one of which rotates relative to the other. In the method for producing biologically ingestible microparticles by separating raw materials of biologically ingestible microparticles by a neutralization reaction in a fluid, the fluid is formed into a thin film fluid between two processing surfaces arranged so as to be able to approach to and separate from each other, at least one of which rotates relative to the other, and biologically ingestible microparticles are separated by a neutralization reaction in the thin film fluid. A solution containing a first solvent in which a chemical as a main eye drop component is dissolved, and a solvent capable of serving as a second solvent in which the solubility of the chemical is lower than in the first solvent, are mixed in a thin film fluid formed between two processing surfaces arranged so as to be able to approach to and separate from each other, at least one of which rotates relative to the other, thereby separating drug particles and providing suspended eye drops based on the drug particles.

Priority: JP20070179098 Applic. Date: 2007-07-06; JP20070179102 Applic. Date: 2007-07-06; JP20070179104 Applic. Date: 2007-07-06; JP20070180349 Applic. Date: 2007-07-09; JP20070203850 Applic. Date: 2007-08-06; JP20070214821 Applic. Date: 2007-08-21; WO2008JP62234 Applic. Date: 2008-07-04

Inventor: ENOMURA MASAKAZU [JP]


Application No.: US20100323029A1  Published: 23/Dec/2010

Title: FIVE-COORDINATE NEUROGLOBIN AND USE THEREOF AS A BLOOD SUBSTITUTE

Applicant/Assignee: THE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND WAKE FOREST UNIVERSITY

Application No.: 12/817085   Filing Date: 16/Jun/2010

Abstract:Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood.

Priority: US20090187527P Applic. Date: 2009-06-16

Inventor: GLADWIN MARK T [US]; KIM-SHAPIRO DANIEL B [US]; TISO MAURO [US]


Application No.: US20100329976A1  Published: 30/Dec/2010

Title: NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 12/870749   Filing Date: 27/Aug/2010

Abstract:Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2007-928250 Applic. Date: 2007-10-30; US2003-392403 Applic. Date: 2003-03-20; US2010-729018 Applic. Date: 2010-03-22; US2007-650412 Applic. Date: 2007-01-08; US2002-323736 Applic. Date: 2002-12-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21; US20020366542P Applic. Date: 2002-03-25; US20020365540P Applic. Date: 2002-03-20

Inventor: MERISKO-LIVERSIDGE ELAINE [US]; BOSCH H WILLIAM [US]; CARY GRETA G [US]; PRUITT JOHN [US]; RYDE TUULA [US]; JAIN RAJEEV [US]; WALTERS AMY [US]


Application No.: US20100330083A1  Published: 30/Dec/2010

Title: PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS

Applicant/Assignee: GENENTECH, INC

Application No.: 12/822071   Filing Date: 23/Jun/2010

Abstract:A solution is provided comprising about 0.01-0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline. Such solution is useful for delivery from a catheter and for treating a thrombotic disorder by exposing fibrin-rich fluid from the disorder to an effective amount thereof, as well as in kits. In a preferred embodiment, peripheral thrombosis is treated in a mammal comprising delivering to the mammal via a catheter an effective amount of this solution.

Priority: US2006-533305 Applic. Date: 2006-09-19; US2003-697142 Applic. Date: 2003-10-30; US20020426616P Applic. Date: 2002-11-14

Inventor: SEMBA CHARLES P [US]


Application No.: US20100330604A1  Published: 30/Dec/2010

Title: QUANTIFICATION OF CHANGES IN THE DEGREES OF ORDER OF CELLULAR AND VIRAL MEMBRANES AND APPLICATIONS TO DIAGNOSIS, TREATMENT AND DRUG SCREENING

Applicant/Assignee:

Application No.: 12/733474   Filing Date: 05/Sep/2008

Abstract:A method for characterizing cell membrane order in a cell. The method includes: staining the cell with di-4-ANEPPDHQ to produce a stained cell

irradiating the stained cell with an excitation light, the excitation light being capable of inducing fluorescence in the di-4-ANEPPDHQ

measuring a fluorescence spectrum of the stained cell

and characterizing the cell membrane order by computing a spectral signature of the stained cell from the fluorescence spectrum, the spectral signature providing a character of the cell membrane order.

Priority: US20070935871P Applic. Date: 2007-09-05; US20080129036P Applic. Date: 2008-06-02; WO2008CA01625 Applic. Date: 2008-09-05

Inventor: LABARTHE BENOIT [CA]; MAGUY ANGE [CA]; BONNEFOY ARNAUD [CA]; THEROUX PIERRE [CA]


Application No.: US20100331813A1  Published: 30/Dec/2010

Title: Intravascular Cerebral Catheter Device and Method of Use

Applicant/Assignee:

Application No.: 12/876786   Filing Date: 07/Sep/2010

Abstract:Cerebral Catheter devices and methods for use are provided. The catheter devices provided may include an anti-thrombotic agent coating on the exterior surface. The catheter devices may include unique tip configurations to allow improved fluid delivery capabilities. Further, the catheter devices may also or alternatively include one or more sensor devices in communication with a controller that allow automatically adjusting the delivery of a therapeutic fluid, for example a vasodilator, in response to the condition sensed by the catheter device, such as increased pressure. Moreover, the catheter devices may also be used in conjunction with blood flow transducers to detect and timely prevent and treatment vasospasms or other conditions. Methods for preventing and treatment vasospasm, neoplasm, or other pathological conditions while prolonged using the catheter device are also provided.

Priority: WO2009US38071 Applic. Date: 2009-03-24; US20080038922P Applic. Date: 2008-03-24

Inventor: ROBINSON JOE SAM [US]

...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
US Applications Published in 2011
US Applications Published from 2006-2009
US PROVISIONAL PATENT APPLICATIONS IN BLOOD ANTICLOT TECHNOLOGY PUBLISHED IN 2010
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included drugs, medications, formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors,
heparin, warfarin and related technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve and select highly
relevant documents.
Clck to enlarge and view details